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 Smith-Magenis syndrome (SMS) is a multiple congenital abnormalities intellectual 
disability syndrome that results from a deletion of chromosome 17p11.2 or mutation of the 
retinoic acid inducted one gene (RAI1).  SMS is characterized by a multitude of phenotypic 
features including craniofacial defects, short stature, obesity, intellectual disability, self-abusive 
behavior, sleep disturbance and behavioral abnormalities.  Interestingly, although SMS is a 
clearly defined syndrome with a known molecular change at its foundation, ~40% of all 
candidate cases sent to the Elsea lab for evaluation do not have a mutation or deletion of RAI1.  
We hypothesize that at least one other locus must be responsible for this Smith-Magenis-like 
(SMS-like) phenotype.   
 To address this hypothesis, we first compiled a cohort of 52 subjects who had been 
referred to the Elsea lab for a clinical diagnosis of SMS.  Once these individuals were confirmed 
to not have an RAI1 mutation or deletion, their phenotypes were compiled and statically analyzed 
to distinguish whether SMS and SMS-like cohorts are different in the prevalence of the core 
phenotypes of SMS such as, but not limited to, sleep disturbance, self-abusive behavior and 
 xv
developmental delay.  SMS-like and SMS cohorts are not different in prevalence for these core 
features.  Next, all SMS-like subjects were sent for whole genome array comparative genomic 
hybridization (aCGH) to identify duplications or deletions of each individual’s genome which 
contribute to the phenotype observed.  We identified 6 pathogenic copy number variants (CNVs) 
in six individuals which contribute directly to the clinical phenotype, including two del(2)(q37).  
This study enabled us to draw relationships between SMS and other syndromes that had never 
been appreciated before and helped to identify pathways in which RAI1 may function.  
 Using the data from our SMS-like study we were able to further characterize two known 
syndromes; Deletion 2q37 syndrome (brachydactyly mental retardation syndrome) and deletion 
2q23 syndrome. With regard to deletion 2q37, syndrome we used genomic data from known and 
new deletion 2q37 subjects to refine the critical region to one gene: the histone deacetylase 4 
gene (HDAC4).  Using both clinical and molecular clues, we were able to identify one subject 
from our SMS-like cohort who has an insertion in HDAC4 which results in a premature stop 
codon.  We conclude from this study that mutation of HDAC4 results in brachydactyly mental 
retardation syndrome.   
 With regard to deletion 2q23 syndrome there were only five known cases in the published 
literature to which we were able to add two more.  Using as similar approach to our del2q37 
study we refined the critical region for this syndrome to one gene, the methyl binding domain 5 
gene (MBD5).  Using a molecular and clinical approach we were able to conclude that 
haploinsufficiency of MBD5 results in the core phenotypes seen in del2q23 syndrome including 
microcephaly, intellectual disabilities, severe speech impairment, and seizures. 
 Using all the data generated from the three previous studies we set out to characterize the 
molecular function of RAI1.  We hypothesize that RAI1 is a transcription factor that regulates 
 xvi
gene expression of core genes involved in development, neurological function, and circadian 
rhythm.  Using a ChIP-chip based approach we identified 257 transcripts we believe RAI1 
regulates.  Following up on these transcripts, using in vitro and in vivo methods, we have been 
able to conclude that RAI1 is a positive regulator of CLOCK, the master regulator of the central 
circadian cycle.  
 Taken together, these studies have given us insight into the specific molecular changes 
that contribute to SMS and SMS-like syndromes.  We have unveiled pathways and genes which 
are important to normal human development and behavior and identified novel functions of 
RAI1.  These studies will provide the foundation for the future discovery of the pathways 
affected.   
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Chapter 1: Background and literature review 
Introduction 
 Smith-Magenis syndrome (SMS, OMIM#182290) is a congenital abnormalities, 
intellectual disability syndrome that can present with sleep disturbance, self-abusive and 
aggressive behavior, craniofacial abnormalities, neurological abnormalities, and obesity.  First 
described by Ann Smith and Dr. Ellen Magenis, SMS was initially thought to be a contiguous 
gene syndrome resulting from a deletion of the 17p11.2 region [3].  However, later molecular 
evidence revealed one gene contributes to the majority of the phenotypes observed.  Data 
revealed that mutation or deletion of the retinoic acid induced 1 gene (RAI1) resulted in SMS 
[4].  Thus, SMS is a sporadic, dominant syndrome defined by haploinsufficiency of RAI1.    
 Duplications and deletions of the genome have long been thought to contribute to 
evolution of all species.  While there are rare cases for these copy number changes to confer an 
advantage to said species, these types of changes are typically detrimental.  Deletion and 
duplication syndromes are a major contributor to the overall number of recognized intellectual 
disability syndromes which are being identified and characterized at a rapid pace with the advent 
of new technologies such as whole genome array comparative genomic hybridization (aCGH) 
[5].  SMS, duplication 17p11.2 syndrome (also known as Potocki-Lupski syndrome), fragile X-
syndrome, and Williams syndrome all result from a duplication or deletion of specific regions of 
the genome.  
 Typically, deletion syndromes are more common and phenotypically more severe than 
duplication syndromes, due to haploinsufficiency, one copy not being sufficient, of one or more 
core genes (a gene imperative to the proper function of the disrupted pathway).  When a 
chromosomal region is duplicated, the resulting phenotype can be more subtle and is thus more 
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likely to be missed by a clinician, not warranting a molecular evaluation [6].  So, it is more 
appropriate to state that the incidence of deletion and duplication events in the population is 
likely very similar, however, the identification of these events is more likely to yield the 
unveiling of a deletion as the cause of the phenotype observed [7, 8].  This can be seen in SMS 
versus duplication 17p11.2 syndrome where the intellectual disability, craniofacial, sleep, and 
metabolic abnormalities are much more severe in SMS and the number of subjects identified 
with a 17p11.2 duplication is ~75 whereas more than 300 SMS subjects have been confirmed 
[7].  There is, however, some evidence showing that in the SMS region, on 17p11.2, deletions 
are twice as likely to occur than duplications [8].  This being said, the molecular events that take 
place which results in these two outcomes, duplication vs. deletion, are similar and due to non-
allelic homologous recombination (NAHR) which is mediated by segmental duplications in the 
17p11.2 region [9] (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 3 
 
 
 
 
 
 
 
Figure 1.  Mechanism for non-allelic homologous recombination.  A) Grey and black arrows 
indicate regions of homology between sister chromatids.  NAHR can occur in two forms: B) 
Intramolecular, wherein sister chromatids misalign leading to deletion of intervening sequences.  
C) Intermolecular, wherein chromatids from different chromosomes misalign leading to a 
duplication or deletion allele. Modified from Turner et al. 2008 [8].  
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Copy Number Variation (CNV) 
 Copy number variations are defined as segments of DNA ranging from 1 kilobase (kb) to 
several megabases (Mb), for which copy-number differences have been revealed by comparison 
of two or more genomes [10].  Investigation into the importance of copy number variations has 
become an integral part in understanding human evolution and disease.  Various molecular 
events can result from CNV, including gene dosage, gene disruption, gene fusion and position 
effects, CNVs can cause Mendelian or sporadic traits [11], or be associated with complex 
diseases [12].  CNVs can also represent singularly benign polymorphic variants that contribute to 
a combinatorial effect in variation.  In fact, it is thought that CNVs contribute more to human 
variation than do single nucleotide polymorphisms [13].  Additionally, it is thought that CNVs 
have a much higher de novo, locus specific mutation rate than SNPs [11].  Given these facts, it is 
important to study disorders and syndromes which result from CNV to better understand and 
recognize regions of the genome that may contribute in large part to disorder or variation.    
 
Smith-Magenis syndrome 
    Smith-Magenis syndrome is a recognizable syndrome characterized by physical, 
developmental, neurological, and behavioral features. SMS is typically a de novo disorder with 
an estimated prevalence of 1:15,000–25,000 live births [14] however; there is one report of an 
SMS subject having a mother who is mosaic for a del(17)(p11.2) [15].  SMS has many clinical 
phenotypes that overlap with other intellectual disability syndromes, such as Prader-Willi and 
Williams syndromes, and interestingly only ~46% of those individuals referred the Elsea lab for 
17p11.2/RAI1 molecular evaluation are positive for molecular changes leading to SMS (Elsea, 
unpublished data).   
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Physical features consist of distinctive craniofacial and skeletal anomalies including 
brachycephaly, frontal bossing, hypertelorism, synophrys, up slanting palpebral fissures, midface 
hypoplasia, a broad square-shaped face flat nasal bridge and a tented upper lip [16]. Dental 
anomalies include tooth agenesis, especially of premolars, and taurodontism [17]. Cleft lip or 
palate is also reported at a higher rate than seen in the normal population [18] and hearing loss is 
present at 60-68%. 
 The neurological and behavioral phenotypes seen in SMS consists of hypotonia, 
stereotypies such as self-hugging and hand twirling, self-abusive behavior, hyperactivity, and 
oral and/or motor dysfunction [18, 19].  An inverted circadian rhythm which results in waking 
periods during the night and napping periods during the day, and times of activity, complicate 
the neurological and behavioral phenotypes observed [20].  
Skeletal and developmental abnormalities include short stature (<5th percentile), 
brachycephaly, brachydactyly, scoliosis, fifth-finger clinodactyly, fore arm and elbow 
limitations, and polydactyly.  Additionally obesity is observed and cardiac defects are present at 
~30% [18, 20].   
Otolaryngological abnormalities such as hearing loss, a hoarse deep voice, and vocal cord 
nodules and polyps are also common [21, 22, 23]. Additionally, ophthalmologic features are 
present in 64% of SMS patients and include myopia, iris anomalies such as heterochromic irides 
or Wolfflin-truckmann spots (iris hamartomas), strabismus, microcornea, and rarely, retinal 
detachment (which can result from violent behaviors) [18, 24, 25]. 
 
 
 
 6 
Intellectual disability  
Intellectual disability (ID) is defined as a person having an IQ <70 and is present in 1–3% 
of the general population.  The cause of ID is unknown in more than half of cases identified [26]. 
Most SMS individuals have mild to moderate intellectual disability with IQ ranging 
between 20-78 and most children falling between 40-54 [22]. School-age children with IQs in 
the low normal range have been identified; however, IQ decreases as the child ages ultimately 
placing the individual in the mild intellectual disability range by adulthood (Elsea, unpublished 
data). Delayed speech occurs in ~84% of SMS patients [27]. These individuals have better 
receptive language skills than expressive language, while their social-emotional functions remain 
within the normal range [28, 29]. In addition, delayed fine/gross motor skills, problems with 
sensory integration, and poor adaptive function are seen. Other neurological features include 
peripheral neuropathy, pes cavus or pes planus, abnormal gait, and decreased sensitivity to pain, 
which may lead to an increased risk for self-injury.  
 
Sleep and circadian rhythm abnormalities 
Sleep disturbance is a hallmark of Smith-Magenis syndrome.  It is reported that 75%-
100% of all confirmed SMS cases present with sleep disturbance and this is one of the early 
indicators that an individual may have SMS [19, 22].  Infants typically present with 
hypersomnolence early in life, and sleep disturbance in older children include difficulty falling 
asleep, inability to enter or maintain REM sleep, reduced night sleep, shortened and broken sleep 
cycles with frequent night time and early-morning awakenings and excessive daytime sleepiness 
[20, 30] (Figure 2).   
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Figure 2.  Circadian sleep pattern of SMS subject.  5 year old confirmed SMS subject.  Data 
collected over a 16 day period using a wrist activity meter.  Top bar indicates wake periods 
(white) and sleep periods (black).  Vertical black lines indicate periods of activity.  Note 
consistent night time arousals and day time naps. Modified from Gropman et al. 2006 [28]. 
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Thought to be caused by an inverted rhythm of melatonin secretion, these circadian 
rhythm difficulties can complicate behavioral and learning difficulties (Elsea, unpublished data).  
However, multiple cases have been reported that have normal melatonin secretion but still have 
sleep disturbance, indicating a possible molecular role for RAI1 in the sleep cycle and the core 
molecular pathway of circadian rhythm. [30]   
 
Behavioral abnormalities 
The SMS phenotype consists of core behavioral abnormalities.  Core phenotypes include 
attention-seeking, aggression, disobedience, a lack of respect for personal space, distraction, 
stereotypical and self-injurious behaviors.  Interestingly, self-injurious behaviors are seen in 
~90% of cases and include head-banging and skin picking, two features unique to SMS, 
onychotillomania, and polyembolokoilamania are more often seen in older children [31, 32].  
Stereotypical behaviors include self-hugging, hand twirling, and body rocking [31, 33].  It is 
noteworthy that although some SMS subjects are diagnosed with autism early in life (because of 
delayed speech), this diagnosis typically changes with the acquisition of language skills.    
 
Craniofacial and skeletal abnormalities 
 Craniofacial and skeletal abnormalities include short stature, broad face, flat nasal bridge, 
brachycephaly, brachydactyly, scoliosis, crainostenosis, prognathasism, midface hypoplasia, 
tented upper lip, and cleft lip and/or palate.  The range of craniofacial phenotypes is variable 
early in life but as subjects age there is a “typical” appearance that becomes identifiable (Figure 
3) 
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Figure 3.  Craniofacial features observed in Smith-Magenis syndrome.  A-C Common 
deletion. D-F Atypical deletion. G-I RAI1 mutation.  Modified from Girirajan et al. 2006 [34] 
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Other abnormalities   
Along with the typical behavioral, neurological, and craniofacial features there are some 
phenotypes in SMS that are more variable.  Dental abnormalities are observed in ~50% of 
subjects and include malocclusion, tooth agenesis, taurodontism, gingavitus, and poor overall 
dental hygiene [17].   
Cardiac abnormalities are also seen in a subset of SMS subjects and include ventral septal 
defect, atrial septal defect, tricuspid stenosis, mitral stenosis, tricuspid and mitral regurgitation, 
aortic stenosis, pulmonary stenosis, mitral valve prolapse, tetralogy of Fallot, and total 
anomalous pulmonary venous return [18].   
Seizures occur in up to 30% of cases and affect those with a common deletion at the 
highest rate.  However, ~50% of diagnosed SMS cases present with abnormal EEGs [18].  This 
suggests that up to 20% of individuals with SMS do not reach the threshold for seizure.   
 
Variation in SMS deletion 
 17p11.2 deletions leading to SMS can be broken down into four main categories; 
common, large, small and atypical deletions (Figure 4).  All deletions encompass the RAI1 gene 
but size and position of the deletion can account for phenotypic variance present in the 
individual. For example, short stature is seen at a higher prevalence in individuals with common 
deletions than those found to have large deletions [18].  Those with small deletions are more 
likely to have an abnormal EEG than those with common deletions [18].  Additionally, those 
with small deletions have a more similar phenotype to individuals with RAI1 mutations [14].  
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Figure 4.  Deletion variation identified in SMS.  Loci and FISH probes used to test for 
presence or absence of these loci are represented in the first two columns.  Shaded boxes 
represent regions not deleted and empty boxes indicate regions that are deleted.  Shown are 
common, large, small and atypical deletions seen in SMS.  Note that RAI1 is found in all 
deletions.  Modified from Girirajan et al. 2006 [34].   
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Duplication 17p11.2 syndrome (Potoki-Lupski syndrome, PTLS)  
 Interstitial duplication of 17p11.2 results in duplication 17p11.2 syndrome, also known as 
Potoki-Lupski syndrome (PTLS).  Dup(17)(p11.2) results in mild to severe intellectual disability, 
infantile hypotonia, failure to thrive, congenital cardiovascular anomalies, sleep-disordered 
breathing, developmental delay, intellectual disability, hyperactivity, and autism [35, 36].  
Craniofacial features include a triangular face, microcephaly, micrognathia, broad nasal bridge, 
high arched palate, and hypertelorism, while dental anomalies in the form of malocclusion of the 
teeth have also been reported [37].  Limb abnormalities including flexion deformity of the 
fingers and club foot have also been described. Other features include cognitive and language 
impairment, pharyngeal dysphasia, obstructive and central sleep apnea, structural cardiovascular 
abnormalities, and electroencephalogram (EEG) abnormalities [35, 36] 
Less commonly reported features are hearing impairment, structural otolaryngological 
defects, and ophthalmic abnormalities, such as myopia and iris hamartoma. Other rarely reported 
features are genitourinary and/or renal anomalies, scoliosis, and hypercholesterolemia [36].  
The predicted incidence of dup(17)(p11.2) syndrome are the same as that of SMS 
(~1:25,000) but is likely under diagnosed because the phenotype can be much more subtle than 
that of SMS.  Only ~75 cases of dup(17)(p11.2) syndrome have been reported [7].  However, a 
recent report indicates that this region may be subject to germline rates of deletion to duplication 
of 2.14:1, indicating a molecular preference for deletion over duplication in 17p11.2 [8].   
Duplication of this 17p11.2 region can range between a 0.4 Mb to 13.3 Mb with 3.7 Mb 
being the most common duplication (between distal and proximal repeats flanking RAI1)  and 5 
Mb being the least common duplication (located between LCR17pA and LCR17pD) having been  
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recently identified in two individuals [7].  A list of features with regard to the different 
classifications are seen in Table 1. 
 
Mouse models for Smith-Magenis and duplication 17p11.2 syndromes 
Mouse models that mimic human conditions are invaluable tools to help understand the 
molecular, developmental, and behavioral role of a gene or genes.  The sequencing of the mouse 
genome has allowed for regions of synteny to human genomic sequence to be mapped and 
utilized for research [38].  
Three types of genetically engineered mice are typically used for research and are 
knockout, gene-trap, and transgenic.  Knockout and gene-trap serve the purpose to eliminate a 
given gene or region from expression and function whereas transgenic mouse models contain 
genomic material used to over express, or simply express foreign DNA.  
Murine chromosome 11qB1.3-B2 is syntenic to human chromosome 17p11.2.  An 
approximate 34 cM region surrounding RAI1/Rai1 is conserved between mouse and human 
genomic structure making this region fit for creation of knockout and transgenic mice (Figure 5).  
Mice lacking Df(11)17/+ or duplicated for Dp(11)17/+ a 2 Mb region, containing seven genes, 
syntenic to human chromosome 17p11.2 were originally created by Waltz et al. 2003 [39] using 
chromosome engineering technology.  These deletion/duplication mice were created to mimic 
the common deletion seen in SMS and duplication seen in dup(17)(p11.2) syndrome.  These 
mice recapitulate many of the core features observed in SMS and duplication 17p11.2 syndrome.   
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Table 1.  Clinical features of chromosome 17p11.2 duplication cases.  Data collected from 
Girirajan et al. 2007 [40] and Zang et al. 2010 [7].  
dup(17)(p10p12) dup(17)(p11.2p12) dup(17)(p11.2p11.2) 
Uncommon 
dup(17)(p11.2p12) Clinical features 
 N=4 N=7 N=8 N=2 
Mental retardation 4/4 7/7 8/8 2/2 
Pre/postnatal growth retardation 3/4 7/7 3/3 0/2 
Motor delay 4/4 7/7 2/3 N 
Speech delay 4/4 5/5 2/4 N 
History of spontaneous abortions 1/3 N N N 
Hypotonia 4/4 2/3 2/4 1/1 
Feeding difficulties 4/4 3/4 1/3 2/2 
Hyperactivity/behavioral abnormalities 1/3 2/5 4/6 2/2 
Seizures 2/4 1/6 3/7 0/2 
Decreased nerve conduction ¼ 5/6 0/8 0/2 
Delayed deep tendon reflexes 1/4 6/7 0/8 N 
Craniofacial features        
Triangular face 3/3 2/4 1/2 2/2 
Microcephaly 4/4 2/3 4/6 N 
Micrognathia 3/4 1/4 2/3 N 
Hypertelorism 2/4 3/3 1/3 N 
Broad nasal bridge 4/4 4/5 2/4 0/2 
Low-set/malformed ears 2/4 4/4 3/3 0/1 
High arched palate 1/4 3/5 3/4 N 
Cleft lip/palate 0/4 0/7 1/4 N 
Ophthalmologic disorders  2/4     2/2 
Short broad neck N 1/7 N 0/2 
Hearing loss 1/4 1/7 1/3 0/1 
Cardiac anomalies  0/4  2/7 0/8  0/2 
Renal/urinary tract anomalies 1/4 1/7 2/8 1/1 
Short stature 1/4 6/6 5/8 N 
Decreased weight 1/4 4/4 3/5 0/2 
Bone and limb defects        
Clinodactyly of fifth finger N 4/7 2/8 N 
Flexion contractures 1/4 3/7 0/8 N 
Foot anomalies 2/4 6/7 0/8 N 
Short sternum N 1/6 N N 
Dental anomalies 1/4 4/7 5/8 N 
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Df(11)17/+ mice have features consistent with SMS including craniofacial abnormalities, 
obesity, seizures and neurobehavioral abnormalities including an abnormal circadian rhythm 
[39].  Neurological abnormalities were observed including overt clinical seizures and abnormal 
EEGs which are also seen in SMS [39].  Histological examinations were performed with brains, 
hearts, spleens, and kidneys, and no obvious defects were identified in any of these tissues [39] 
which is also consistent with the SMS phenotype. 
Dp(11)17/+ (duplication) mice displayed growth retardation, hyperactivity, increased 
anxiety-related responses in a light-dark test, increased conditioned fear, and decreased startle 
response with normal sensorimotor gating on a prepulse inhibition  
assay [39, 41]. No craniofacial anomalies or altered circadian rhythm were observed in the 
Dp(11)17/+ mice [39, 41].  
Later, using a targeted approach, mice haploinsufficient for Rai1 were created [42].  
These mice were developed to test the phenotypic consequences of Rai1 inactivation and to 
provide insight into the phenotypes Rai1 contributes directly to in SMS.  Young Rai1+/- mice 
were under weight as compared to wild-type littermates but by age 23 weeks became 
significantly larger with progressive weight gain [42] (Figure 6).  Eighteen percent of Rai1+/- 
mice had craniofacial abnormalities, including short curved snouts caused by the malformation 
of the craniofacial skeletal elements [42].   
Rai1-/- mice largely were not viable and Mendelian ratios of litters (+/+ 36.2%, +/- 
59.3%, -/-4.5%) were skewed indicating significant embryonic lethality.  Rai1-/- mice that did 
survive beyond the embryonic stage had growth retardation and craniofacial abnormalities as 
compared to WT litter mates [42].  Additionally, these showed tone and context dependent 
impaired fear conditioning, as well as overt seizures [41, 42]. 
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Figure 5. Mouse synteny to chromosome 17p11.2.  A) Human 17p11.2.  RefSeq Genes (Build: 
February 2009, GRCh37/hg19).  B) Mouse 11qB1.3-B2.  RefSeq Genes (Build: July 2007, 
NCBI37/mm9).  Grey bars between sections A and B represent regions of synteny.  Modified 
from UCSC Genome Browser (http://www.genome.ucsc.edu/)  
 
 
 
 
 
 
 
 
 17 
Recently, Girirajan et al. [43, 44] generated and performed an in-depth behavioral 
analysis of bacterial artificial chromosome(BAC) transgenic, Rai1 overexpression mice (Rai1-
Tg) harboring three copies of the Rai1 gene.  The authors found that these mice exhibited a 
variety of defects.  Growth retardation was seen with these mice being undersized as compared 
to WT litter mates which continued as development progressed.  However, transgenic mice were 
able to achieve normal size by 20 weeks [43].  Abnormal maternal behavior was observed 
wherein Rai1-Tg mothers could not properly take care of their pups (1/5 survival average, WT or 
transgenic pups) [44].  When these pups were placed with a WT foster mother (all, 5/5 average) 
pups survived.  Additionally, Rai1 overexpressing mice exhibit a reduction in the levels of 5-
HIAA suggesting a defect in the enzyme monoamine oxidase (MAO), which converts serotonin 
to 5-HIAA.  Further, these mice have altered social behavior with impaired nesting behavior, 
social dominance, aggression, reduced social memory, hyperactivity, anxiety-related behavior, 
and altered sociability, all 5-HIAA mediated behaviors.        
Taken together, the Df(11)17/+, Rai1 +/-, Dp(11)17/+, and Rai1-Tg mice have proven to 
be good models for their respective syndromes.  The Rai1+/- mice have craniofacial, behavioral 
and developmental abnormalities consistent with those of SMS.  Additionally, Dp(11)17)/+ 
duplication mice have behavioral, neurological and developmental abnormalities consistent with 
that of dup17p11.2 syndrome.  These data reinforce the dosage sensitivity of the retinoic acid 
induced 1 gene.   A summary of the phenotypes seen in these mice can be seen in Table 2  
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Figure 6.  Rai1+/- mice growth rates compared to WT litter mates.  Note obesity and 
shortened snout.  A) Rai1+/- and WT size and craniofacial phenotypes.  B) Growth rates of 
Rai1+/- mice.  Modified from Bi et al. 2005 [42].  
 
 
 
 
 
 
 
 
A B 
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Table 2. Phenotypes of Rai1 engineered mice. Bi et al. 2005, 2007, Waltz et al. 2003, 2004, 2006, Girirajan et al. 2009.   
 Mouse Df(11)17/+ [39, 41] Rai1+/- [42, 45] Rai1-/- [45] Dp(11)1)/+) [39, 41, 46] Rai1-Tg [44] 
Feature       
Craniofacial Defect  + + + - - 
Developmental Defect  + + + + + 
Overweight  + + - - - 
Underweight  - - + + + 
Circadian Rhythm Abnormality   + N/A N/A - N/A 
Impaired Conditioned Fear  + - + + N/A 
Hyperactivity  - - - + + 
Seizure  + + + - - 
Abnormal EEG  + + + - N/A 
Abnormal Maternal Behavior  N/A N/A N/A N/A + 
Altered Mendelian Transmission  + + - + + 
“+” indicates presence of feature.  “-” indicates absence of feature.  “N/A” indicates feature not assessed.
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Unexplained intellectual disability  
 Understanding the molecular basis for intellectual disability continues to be a problematic 
hurdle to jump in the field of human genetics.  ID has a 1-3% prevalence rate in the general 
population [47, 48] and although there are many well-described ID syndromes associated with 
known molecular changes such as SMS (del(17)(p11.2)/RAI1 mutation), Williams syndrome 
(del(7)(q11.23)), Rett syndrome (MECP2 mutation), Prader-Willi (paternal del(15)(q11-q13), the 
molecular basis for ID in many individuals remains unclear.  
  The major genomic and molecular contributors to ID are aneuploidy, chromosomal 
microdeletions or microduplications, translocations, inversions, uniparental disomy (UPD), 
exonic mutation, splice-site or intronic mutation, and epigenetic or imprinting changes. 
Chromosomal deletions and duplications account for the vast majority of ID, however in up to 
80% of all ID cases the molecular change cannot be identified [49, 50, 51].  The most common 
clinical diagnoses of individuals with ID are Down syndrome (9.2%), microdeletion 22q11.2 
(2.4%), Williams–Beuren syndrome(1.3%), fragile-X syndrome (1.2%), Cohen syndrome 
(0.7%), and monosomy 1p36.3 (0.6%) [52]. 
New technologies have evolved to help characterize these ID syndromes, including whole 
genome array comparative genomic hybridization (aCGH), targeted array, high resolution 
fluorescence in situ hybridization (FISH), and high throughput sequencing (both whole genome 
and whole exome) have allowed for faster, and more accurate molecular diagnosis the 
probability of a multiple hit theory exists making the majority of ID fall under the “complex” 
arena of genetic diagnosis [5].    
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Chapter 2 
Identification of loci contributing to the SMS-like phenotype. 
Introduction 
Smith-Magenis syndrome (SMS, OMIM#182290) is a complex congenital 
abnormalities/mental retardation disorder caused by a deletion of chromosome 17p11.2 that 
includes the RAI1 gene or a mutation in RAI1 [4]. Phenotypically, SMS overlaps with other 
syndromes such as Prader-Willi, Williams, and Down syndromes. While certain features overlap 
between these syndromes, the phenotype associated with SMS is characterized by a specific 
combination of traits. In short, SMS can be characterized by developmental delays, craniofacial 
abnormalities, speech and motor delay, neurological abnormalities, sleep disturbance, and self-
injurious behaviors [3]. Due to the dense overlap between mental retardation syndromes, it is 
imperative that the genetic basis for each clinical phenotype is unraveled to provide the most 
complete information for families, to target the most appropriate services for the child, and to 
provide the most accurate recurrence risk assessment. 
We have acquired a cohort of individuals with clinical features of Smith-Magenis 
syndrome in whom a deletion or mutation of RAI1 cannot be identified. We refer to these cases 
as “Smith-Magenis syndrome-like” (SMS-like), since they are not phenotypically distinguishable 
from individuals with a molecularly-confirmed RAI1 mutation or 17p11.2 deletion. Each case is 
evaluated on an individual basis, and if the subject meets the phenotypic criteria for a clinical 
diagnosis of SMS, the coding region of the RAI1 gene is sequenced.  Each subject referred for 
molecular evaluation had a normal karyotype and 17p11.2 FISH analysis, followed by 
sequencing of the RAI1 coding region [53, 54]. Of patients referred to our laboratory for 
RAI1mutation or deletion analysis, 46% (n = 52/112) were confirmed to carry a heterozygous 
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deletion or mutation of RAI1. Although the remaining cases (n = 60/112) have significant 
phenotypic overlap with SMS, they do not have a molecular diagnosis. Thus, we hypothesized 
that at least one additional locus, possibly functioning in a common pathway with RAI1, is 
contributing to the high frequency of this phenotype. Eight of the remaining cases were not 
included in this study because of the lack of genetic material for analysis or insufficient clinical 
data were available for the subject. 
Array comparative genomic hybridization (aCGH) has become an invaluable tool in the 
genomic evaluation of subjects with mental retardation, developmental delay, and congenital 
anomalies, as well as more complex disorders such as autism and schizophrenia [55, 56]. Using 
aCGH as our primary tool, we set out to identify genomic regions potentially containing dosage 
sensitive genes that when deleted or duplicated, lead to an SMS-like phenotype. Analysis of 
these 52 cases revealed copy number abnormalities of chromosomal regions which contain genes 
that contribute to neurological integrity, cognition, and development, all of which when 
disturbed could lead to the phenotypes observed in the SMS and SMS-like groups. Given the 
phenotypic and genetic information presented herein and the loci identified, these data will 
improve diagnosis, provide insight into the etiology of mental retardation/congenital 
abnormalities syndromes, and one day could lead to better treatments and therapy for individuals 
with these genomic disorders. 
 
Materials and Methods 
Subject ascertainment and samples 
Subjects were referred to the Elsea laboratory for molecular evaluation of SMS at 
Michigan State University or Virginia Commonwealth University. Samples were collected in 
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accordance with Institutional Review Board approved protocols from the appropriate institution.  
Peripheral blood was collected, and DNA and metaphase chromosomes prepared following 
standard methods.  All samples then evaluated for mutations in the RAI1 gene. Phenotypic 
information was collected using medical records, geneticist reports, patient photos, and in some 
cases a clinical checklist sent to the referring geneticist. All information was collected in 
accordance with IRB approved protocols. 
 
Whole genome array-based comparative genomic hybridization (aCGH) 
aCGH was performed as previously described [40]. The procedures for the construction, 
hybridization, and data analysis is described below. 
Construction of the human BAC CGH array: DNA printing solutions were prepared from 
sequence connected RPCI-11 BAC by ligation-mediated PCR as described previously 
[57,[58,[59].  The minimal tiling RPCI BAC array contains ~19,000 BAC clones that were 
chosen by virtue of their STS content, paired BAC end-sequence and association with heritable 
disorders and cancer.  The backbone of the array consists of ~4600 BAC clones that were 
directly mapped to specific, single chromosomal positions by fluorescent in situ hybridization 
(FISH) [57]. Each clone is printed in duplicate on amino-silanated glass slides (Schott Nexterion 
typeA+) using aMicroGrid ll TAS arrayer (Genomic Solutions, Inc.). The BAC DNA products 
have ~80 µm diameter spots with 150µm center to center spacing creating an array of ~39,000 
elements. The printed slides dry overnight and are UV-crosslinked (350mJ) in a Stratalinker 
2400 (Stratagene) immediately before hybridization. A complete list of the RPCI-11 BAC clones 
spotted on the 19K array can be found at: http://microarrays.roswellpark.org. 
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Labeling and hybridization of DNA: Reference and test sample genomic DNAs (1 µg each)are 
individually fluorescently labeled using the BioArray CGH Labeling System (Enzo Life 
Sciences). Initially, DNA is denatured in the presence of a random primer at 99° C for 10 min in 
a thermocycler, and then quickly cooled to 4°C. The tubes are transferred to ice and labeling 
occurs with the addition of dNTP-cyanine 3 mix (or dNTP-cyanine 5) and Klenow fragment.  
Incubation takes place for 4 h at 37° C in a thermocycler.  The unincorporated nucleotides were 
removed using a QIAquick PCR purification column (Qiagen), and the labeled probe is eluted 
with 2 x 25 ul washes. Prior to hybridization, the test and reference probes were combined with 
100 ug human Cot-1 DNA (Invitrogen) and precipitated for one hour with sodium acetate and 
ethanol. The probes are pelleted, resuspended in 110 µl SlideHyb Buffer #3 (Ambion) containing 
5 µl of 100 µg/µl yeast tRNA (Invitrogen), heated to 95°C for 5 min, then incubated at 37°C for 
30 min. Hybridizations to the 19K BAC arrays were performed for 16 h at 55° C using a 
GeneMachine hybridization station (Genomic Solutions, Inc.) as described [60]. After 
hybridization, the slides are automatically washed in the GeneTAC station with reducing 
concentrations of SSC and SDS. aCGH was also performed under similar conditions as a fee for 
service at Empire Genomics using the same BAC CGH array as previously described [40]. 
Image and data analyses: The hybridized aCGH slides are scanned using a GenePix 
4200AL Scanner (Molecular Devices) to generate high-resolution (5 µm) images for both Cy3 
(test) and Cy5 (control) channels. Image analysis was performed using the ImaGene (version 
8.0.0) software from BioDiscovery, Inc. The log2 test/control ratios were normalized using a 
sub-grid loess correction. Mapping information was added to the resulting log2 test/control 
values. The mapping data for each BAC are found by querying the human genome sequence at 
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http://genome.ucsc.edu, and BACs in regions of segmental duplication or large-scale variation 
are flagged. 
 
Fluorescence in situ hybridization 
In order to determine the presence of a 17p11.2 deletion (which would indicate Smith-
Magenis syndrome), metaphase chromosomes were prepared for each patient in whom clinical 
FISH had not been previously reported. RAI1 FISH was performed as previously described [53]. 
A minimum of 10 metaphase spreads and 10 interphase nuclei were observed for each case 
evaluated. 
 
Sequencing of RAI1  
Overlapping RAI1 primers covering the entire coding region (exons 3-6, NM_030665) 
and the intron-exon junctions were designed to PCR-amplify the patient DNA samples. 
Sequencing of RAI1 was performed as previously described [34].   
 
Bioinformatic and statistical analyses  
Deleted or duplicated BACs were located on the UCSC Genome Browser 
(http://www.genome.ucsc.edu/), Human Mar. 2006 assembly, and genomic position determined 
for BACs that flanked the deletion or duplication (and were included in the aberration).  
Prevalence of features in SMS and SMS-like cohorts were analyzed by Fisher’s exact test 
utilizing a web-based program located at  http://www.langsrud.com/fisher.htm. P-values ≤ 0.05 
were considered statistically significant. 
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Results 
SMS vs. SMS-like phenotypes 
We have assessed the phenotypes of 52 SMS-like cases and compared the overall 
features of this cohort to those compiled in a meta-analysis of all the known and reported SMS 
cases (Table 3) [18]. As evident in the SMS-like cohort, the most common phenotypic features 
are not different in prevalence between this group and the SMS cohort (Table 3). We propose 
that even though RAI1 is the major contributor to SMS, other players in the “SMS pathway”, 
when duplicated or deleted, result in a similar phenotype. The SMS and SMS-like cohorts are 
very similar (Table 3). Sleep disturbance, developmental delay, self-injurious behavior, 
hyperactivity, oral/motor dysfunction, hypotonia, dental anomalies, chronic ear infections, 
digestive problems, obesity, and neurological abnormalities were not different in prevalence 
between the two groups and were present in the majority of subjects (Table 3). These 
commonalities led us to hypothesize that at least one other locus exists and contributes to the 
global SMS phenotype and/or disruption of a common pathway leads to this phenotype. 
 
Whole genome array comparative genomic hybridization 
Once this SMS-like cohort was collected and all testing was negative for classical SMS 
by molecular techniques (see Methods), DNAs were then evaluated by whole genome array 
comparative genomic hybridization using a 19,000 RPCI-11 BAC array. We identified 15 copy 
number variants (CNVs) not previously described in these subjects (Table 4, 5). These variants 
occur in 21% (11 out of 52) of our population. Within these 15 CNVs, 8 chromosomes are 
represented, and similar variants are found in multiple cases (Table 4, 5). These CNVs are of 
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Table 3.  Phenotypic features observed in Smith-Magenis syndrome-like cohort. 
Common feature Cohort  
 
SMS1 
(del17p11.2 or  
RAI1 mut) 
SMS-like2 
(negative for 
RAI1  
del or mut) 
 
Developmental delay 100% 100%  
Stereotypies 59% 84% * 
Self-injury 90% 90%  
Sleep disturbance 88% 97%  
Self-hugging/tics 63% 55%  
Hyperactivity 74% 77%  
Seizures 28% 56% * 
Hypotonia 71% 72%  
Signs of peripheral 
neuropathy 86% 72%  
Oral/motor dysfunction 85% 70%  
Craniofacial abnormalities 89% 70% * 
Eye abnormalities 87% 59% * 
Ear abnormalities 63% 64%  
Hearing loss 60% 39%  
Ear infections 90% 69% * 
Dental anomalies 54% 73%  
Cleft lip/palate  15% 2% * 
Hoarse voice 86% 50% * 
Overweight 33% 53%  
Hypercholesterolemia 41% 23%  
Heart defect 31% 11% * 
Digestive problems 95% 67% * 
Short stature 67% 43% * 
Brachydactyly 79% 47% * 
Scoliosis 32% 34%  
 
1Values for SMS cohort taken from Edelman et al 2007 (n=105).  2Cases reported in this 
study (n=52).  Statistics calculated with Fisher’s Exact Test where *=p-value <0.05.  
Range of age at evaluation: 2-44 years for SMS-like cases and 4 months -72 years for 
SMS cases (Edelman et al 2007 [18]).   
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particular interest because of the potential to further define regions of variation that contribute to 
the SMS-like phenotype, given common genes that are either deleted or duplicated. Common 
and possibly polymorphic BACs were excluded by referencing a control group containing 372 
individuals from the National Institute of Mental Health (NIMH) Genetics Initiative as control 
samples [61]. 
 
Pathogenic copy number variants 
Of the 15 CNVs identified in this cohort, some have been previously described but none 
have been reported in cases with phenotypic overlap to SMS. Described below are the CNVs 
believed to be pathogenic and thus, contribute directly to the observed phenotype (Table 4). 
• Monosomy 1p36.32-p36.33, identified in SMS203 (Figure. 7, Table 4), is associated with 
mental retardation, developmental delay, hearing impairment, seizures, growth delay, hypotonia, 
hyperphagia, brachydactyly, self-abusive behavior, obesity, and a Prader-Willi-associated 
phenotype [62, 63]. SMS203 is a 44 year old adult female referred for lifelong sleep difficulties 
and learning and behavioral problems who presented with short stature, obesity, prognathism, 
dental abnormalities, brachydactyly, scoliosis, eye abnormalities, chronic ear and respiratory 
infections, and self-injurious behavior. A strong overlap between phenotypes can be seen 
between both 1p36.33 syndrome and SMS; however, the clinical overlap between these well-
described syndromes has not previously been appreciated. 
• A single case of del(2)(q23.1) (Figure 7, Table 4) was identified in this cohort. This deletion 
was previously reported in association with severe psychomotor retardation, speech impairment, 
epilepsy, microcephaly, ataxia and behavioral disabilities, and described as a pseudo-Angelman  
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Figure 7.  CGH array plots for pathogenic CNVs A) SMS203, del(1)(p36.32-36.33).  B)  
SMS272 and SMS320, del(2)(q37.3)  C) SMS185, del(2)(q23.1)  D) SMS236, dup(4)(p16.1) and 
E)  SMS202, dup(4)(q31.1-q31.2).  Log2 ratio of subject to control shown on y-axis.  CNVs 
were considered significant for duplication or deletion, when flanking BACs held values >0.3 or 
<-0.3, respectively, with 3 consecutive BACs involved in a given abnormality.  Plots were 
created using aCGH viewer (http://falcon.roswellpark.org/aCGHview/).  Genomic data 
illustrating the extent of each deletion or duplication were modified from UCSC Genome 
Browser (http://www.genome.ucsc.edu/) and RefSeq genes are indicated.  Figure not to scale. 
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Table 4.  Pathogenic copy number variants identified in the SMS-like cohort. 
Case # Copy Number Variant (CNV) Genomic Location (bp) Size (Mb) 
SMS203 del(1)(p36.32p36.33)* Chr1:2,171,401-3,037,274 0.86 
SMS185 del(2)(q23.1)*  Chr2:148,543,058-149,504,469 0.96 
SMS272 del(2)(q37.3)+              Chr2:239,764,593-240,938,545       1.17 
SMS320 del(2)(q37.3)* Chr2:237,920,956-240,938,547 3.02 
SMS336 dup(4)(p16.1)*                 Chr4:7,493,733-8,829,348               1.34 
SMS202 dup(4)(q31.1q31.2)*        Chr4:141,648,098-142,218,495       0.57 
Deletions contained flanking BACs below -3.0 log2 ratio.  Duplications contained flanking 
BACs above 3.0 log2 ratio.  CNV location taken from UCSC genome browser, Mar. 2006 build, 
with flanking BACs as reference. CNV confirmation by: *clinical BAC array, +G-Banding.    
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phenotype [64].  SMS185 is a female who presented at age 3.5 y with mental retardation, short 
stature, midface hypoplasia, microcephaly, brachydactyly, hoarse voice, heart abnormalities, and 
hyperactivity but did not exhibit sleep disturbance or self-injurious behavior. Previous 
methylation testing for Angelman syndrome was negative. 
• SMS202 was shown to have a duplication of chromosome 4q31.1-q31.21 (Figure 7, Table 4), 
which has been associated with mild mental retardation and poor language acquisition [65], 
features commonly seen in SMS. SMS202 is a 6 year  
old female with mental retardation, craniofacial abnormalities, 2-3 toe syndactyly, pes planus, 
elbow limitations, sleep disturbance, self-injurious behavior, hyperactivity, and stereotypical 
behaviors. 
• SMS336 is a 3 year old male who carries a novel CNV, dup(4)(p16.1) (Figure 7, Table 4), not 
previously reported in the literature. This region contains 8 known genes and 1 predicted gene, 
including the VPS10 domain containing receptor 2 gene (SORCS2), which is highly expressed in 
the mouse central nervous system. SMS336 presented with a typical SMS phenotype, including 
developmental delays, cognitive impairment, short stature, craniofacial, dental, and eye 
abnormalities, scoliosis, hypotonia, difficulty communicating, hearing loss, chronic ear and 
respiratory infections, decreased sensitivity to pain, heart abnormalities, obesity, sleep 
disturbance, hyperactivity, and self-injurious behaviors. This individual also carries a 
del(14)(q11.2) [66] (Figure 9, Table 6), which is a reported polymorphic CNV.  
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Figure 8.  del2q37 clinical phenotype. A) SMS185 with del(2)(q23.1), age 2 years; B) SMS272 
with del(2)(q37.3), age 15 years; and C) SMS320 with del(2)(q37.3), age 3 years. 
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• A deletion involving 2q37.3 was identified in 2 cases (Figure 7, 8, Table 4): 
o SMS272 is a 15 year old female with midface hypoplasia, brachycephaly, and 
brachydactyly (Figure 8b). Her neurobehavioral phenotype consists of stereotypies, and 
aggressive behavior. She is also obese but does not exhibit sleep disturbance or self-
abusive behavior, both of which are typically seen in SMS. A known polymorphic CNV, 
del(16)(p11.2), was also identified in this case (Figure 7c, 9, Table 6).  
o SMS320 is a 2 year old female with mental retardation, speech and motor delay, sleep 
disturbance, stereotypies, attention-seeking, and self-injurious behaviors (Figure 8c). Her 
craniofacial and skeletal phenotype consists of brachydactyly, brachycephaly, midface 
hypoplasia, tented upper lip, broad, square face, and synophrys. 
• A maternally inherited duplication of 17p12 was identified in SMS348 (Figure 9, Table 6), a 10 
year old male who presented with typical features of SMS. Charcot-Marie Tooth disease type 1A 
(CMT1A) is caused by dup(17)(p12) that includes the PMP22 gene. The associated 
demyelinization of the peripheral nervous system is well-described and does not involve 
developmental delays or sleep disturbance [67, 68]. This finding in SMS348 (Figure 9, Table 6), 
is not causative of the child’s developmental phenotype, with the possible exception that in 
severe cases of CMT1A, peripheral neuropathy may be evident, even in a young child.  
However, del(17)(p12) was recently shown to confer a 10-fold increased risk for schizophrenia 
[69] indicating that gene dosage may predispose an individual to a mild increase in risk (Table 
5). Dup(17)(p12) was also identified in an aCGH study involving 100 mentally retarded 
individuals [70]. 
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Table 5.  Disorders previously associated with the deletions and duplications identified in 
this study. 
CNV Associated phenotype 
del(1)(p36.33) 
Obesity, hyperphagia, dysmorphism, 1p36 deletion syndrome 
[62,[63] 
del(2)(q23.1) Pseudo-Angelman syndrome [64] 
del(2)(q37) Brachydactyly-mental retardation syndrome/AHO-like  [71] 
del(8)(p23.1) Cornelia de Lange alternate locus  [72] 
dup(15)(q11.2) Autism  [73,[74] 
dup(17)(p12) Schizophrenia [70]/autism [75]/mental retardation  [70]/Charcot-
Marie-Tooth disease Type 1A  [67,[68] 
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Non-pathogenic copy number variants  
Several previously reported non-pathogenic CNVs were detected in this cohort as 
described in Table 6. Two of these CNVs were detected in more than one case but are within 
regions of known polymorphisms and thus, not likely to be pathogenic (Figure 9, Table 6). The 
8p23.1 region of deletion contains a cluster of defensin genes and SPAG11B. While these host 
defense genes are not excellent candidates for the syndromes described, predicted genes within 
the deletion region and genes just outside the deleted region, possibly influenced by position 
effects, cannot be ignored. Additionally, SMS279 also carries a dup(16)(p11.2) which flanks the 
reported region associated with autism, neurodevelopmental delay, and dysmorphism [76].  
The 2p11.2 region, deleted in 2 cases in this cohort (Figure 9, Table 6), includes several 
genes that hold potential importance for antibody variation, including IgA, IGVK-A2, and IGV3-
15. Position effects could also be altering gene expression in the regions just outside the common 
deletion, as possible candidates include FABP1 which is associated with age-dependant obesity 
in female mice [77] and FOXI3 which is important in craniofacial development in zebrafish [78]. 
SMS272, who carries a del(2)(q37), also carries a del(16)(p11.2) distal to the recently 
reported autism-susceptibility region (Figure 9, Table 6) [79, 80]. A dup(15)(q11.2) was found in 
SMS202, who also carries a dup(4)(q31.1-q31.2). This deletion region has been associated with 
autism and may contribute to combinatorial effects along with the dup(4)(q31.1-31.2) that is 
thought to be pathogenic. 
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Table 6. Non-pathogenic copy number variations identified in the SMS-like cohort. 
 
Deletions contained flanking BACs below -3.0 log2 ratio. Duplications contained flanking BACs 
above 3.0 log2 ratio. CNV locations taken from UCSC genome browser, Mar. 2006 build, with 
flanking BACs as reference. #Mother also affected with CMT1a. 
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Figure 9.  Non-Pathogenic copy number variants. Array plots for each subject are shown. 
Log2 Ratio of subject to control shown on y-axis. Plots were created using aCGH viewer 
http://falcon.roswellpark.org/aCGHview/). Genomic data illustrating the extent of each case 
deletion or duplication were modified from UCSC Genome Browser 
(http://www.genome.ucsc.edu/). Figure not to scale. 
 
 
 
 41 
Discussion 
In this study, we utilized whole genome aCGH to assess a cohort of 52 clinically well 
characterized patients referred to our laboratory for molecular evaluation of Smith-Magenis 
syndrome. We identified duplications or deletions (15 CNVs in 11 subjects) not previously 
described in these cases, with CNVs in 6 cases that are likely pathogenic and associated with the 
SMS-like phenotype present in the patient (Tables 4, 6). Some of the same genomic 
abnormalities can be found in multiple cases, supporting a common etiology for the similar 
phenotypes. These chromosomal regions include genes that are responsible for fatty acid 
metabolism, neurological development, cell signaling, circadian rhythm, transport, development, 
mental health, neuromuscular function, morphology, and cell cycle control. Because of the 
phenotypic overlap between the SMS and SMS-like cases, a possible indirect role of RAI1 in the 
etiology of these phenotypically similar disorders should be explored [81]. Data from this study 
may give us some insight into the pathways in which RAI1 functions. RAI1 is a putative 
transcription factor that spans ~130 Kb on 17p11.2 and contains 6 exons, 4 of which are coding. 
Bioinformatic analysis of RAI1 has identified a bipartite nuclear localization signal and a PHD 
domain, both of which are consistent with the proposition that RAI1 functions as a transcription 
factor. Although the cases were ascertained based on stringent SMS-phenotypic criteria, 52 cases 
from our cohort neither carried a 17p11.2 lesion nor any pathogenic CNVs. It is possible that 
these cases carry alterations in the yet-uncharacterized regulatory region of RAI1 or a point 
mutation in another critical gene.   
We have also identified multiple variants that are associated with reported syndromes 
(Table 5). This fact speaks to two points: one, there are likely common pathways that lead to the 
phenotypic overlap between SMS and these known syndromes and two, better delineation of the  
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phenotypes and training for diagnosis of these syndromes is needed. In addition, there were 
CNVs that were missed by clinical arrays that did not cover these regions, which supports the 
fact that diagnostic arrays need better coverage over regions that are associated with known 
syndromes.   
One region of variation, del(2)(q37.3), was found in more than one subject in this cohort 
(Figure 9, Table 4). Deletion 2q37 syndrome, also known as brachydactyly-mental retardation 
syndrome or Albright’s hereditary osteodystrophy-like syndrome, is well-described and 
characterized by craniofacial abnormalities, mental retardation, stereotypies, aggressive/self-
injurious behavior, distinct brachydactyly, short stature, obesity, eczema, and sparse hair [82, 
83]. Although the typical craniofacial and skeletal abnormalities previously reported in 
association with deletion 2q37 syndrome do not overlap with SMS [16], the neurological, 
behavioral, and growth abnormalities are similar [18, 24, 34]. Further, SMS272 and SMS320 
exhibit the characteristic brachydactyly type E seen in del(2)(q37) syndrome, which is different 
than the brachydactyly commonly seen in SMS [71, 84]. Both of these subjects also exhibit 
similar craniofacial abnormalities as those in SMS, as well as many of the other features. These 
data emphasize not only the phenotypic overlap between these two syndromes but also expand 
the phenotype of the well-described 2q37 deletion syndrome. These phenotypic and molecular 
overlaps may lead us to candidate genes and pathways that contribute to these complex features. 
Several excellent candidate genes have been identified and warrant further study.  
Potential candidate genes localized to the overlapping deleted region in 2q37.3 include HES6, 
which has been implicated in mRNA transcription regulation and neurogenesis [85], as well as 
SCLY which is implicated in fatty acid metabolism and HDAC4 which is involved in 
chondrogenesis. Given the significant overlapping behavioral and physical phenotype, we 
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propose that one or more genes present in del(2)(q37) syndrome fall in the same pathway(s) as 
those leading to SMS. 
The 1p36.32-p36.33 region deleted in SMS203 contains more than 10 genes. Deleted in 
this region is HES5, a gene important in neuronal development that when reduced in expression 
leads to premature depletion of neuronal stem cells [86], which could also lead to some of the 
neurological phenotypes seen in this patient.   
On chromosome 2q23.1, the MBD5 gene was found to be deleted in a single case using 
SNP array-based technology to assess subjects with mental retardation [1]. MBD5 is a methyl-
CpG binding domain protein. Interestingly this was the only gene deleted in this patient who 
presented with mental retardation, seizures, retarded motor development, and limited social 
interactions, similar to the phenotype of SMS185 in this study.   
Duplicated in the chromosome 4p16.1 region (in case SMS336), SORCS2 is expressed 
throughout the murine central nervous system, including the olfactory bulb, piriform cortex, 
amygdala, hippocampus, median geniculate nucleus, interpeduncular nucleus, and some 
cerebellar Purkinje cells [87]. This gene is thought to be involved with intracellular sorting, and 
altered dosage may contribute to some of the neurological findings such as hypotonia, decreased 
sensitivity to pain, sleep disturbance, self-abusive behavior, hyperactivity, and attention deficit 
disorder. 
UPC1 is duplicated in SMS202, who carries a dup(4)(q31.1-q31.3). Deletion of this gene 
has been shown to cause obesity in mice, whereas duplication of UPC1 is thought to have a 
protective effect [88]. SMS202 is not overweight; however, because of the UPC1 pattern of 
expression in the central nervous system [89], a potential dosage effect should be considered 
regarding neurological abnormalities. 
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Candidate gene sequencing in the subjects wherein no CNV was found is a logical next 
step toward identifying causative genes for the syndromes mapped to the genomic regions 
discussed above. Further, the documented interaction of RAI1 with candidate genes will aid in 
the delineation of molecular pathways causative of the phenotypes described. In conclusion, this 
study is unique in that we have taken a group of patients clinically diagnosed with a very specific 
phenotype, Smith-Magenis syndrome, and identified potentially alternate causative loci. These 
findings will help to improve the diagnosis of individuals with phenotypic overlap to SMS, 
including those with known syndromes that previously were not known to overlap 
phenotypically, such as del(2)(q37) and del(1)(p36) syndromes. The results presented will help 
to further improve diagnosis (both molecular and phenotypic) and potentially treatment of 
microdeletion/microduplication syndromes and will provide insight into the molecular pathways 
involved in these phenotypically complex disorders.   
We propose that, together, Smith-Magenis syndrome and the cases described above, who 
do not have SMS, encompass a group of disorders that are molecularly related and that patients 
with developmental delays, self-injurious behaviors, sleep disturbance, stereotypies, and sudden 
violent outbursts who would otherwise be clinically appropriate for a diagnosis of Smith-
Magenis syndrome be considered for whole genome (not targeted) aCGH in order to identify the 
molecular etiology of the patient’s phenotype. 
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Chapter 3 
Haploinsufficiency of MBD5 associated with a syndrome involving 
microcephaly, intellectual disabilities, severe speech impairment, and seizures 
Introduction 
Owing to the phenotypic complexity of many genomic disorders and the fact that most of 
these disorders result in developmental delays and behavioral problems, overlapping physical 
and behavioral features between syndromes are commonly observed [90]. Although there are 
clear phenotypic differences between most syndromes, Smith–Magenis, Down, and Prader–Willi 
syndromes have many major features in common, including craniofacial features, obesity, and 
hypotonia,  whereas Angelman and Rett syndromes feature seizures and severe developmental 
delays. Correct identification and diagnosis of  specific syndromes are more difficult because of 
these phenotypic similarities.  Ultimately, when comparative genomic hybridization (CGH) data 
are considered and new syndromic regions of the genome are identified, sorting these cases by 
phenotype alone may be even more difficult.  Microdeletion of chromosome 2q23.1 results in a 
novel syndrome previously reported in five individuals [64, 70, 91, 92]. In this study, we report 
two new cases with overlapping 2q23.1 deletions and draw attention to possible candidate genes 
that could be causative for the characteristic phenotype observed in our cases and in the other 
five patients reported in literature. A comparison of phenotypes to the other five known cases 
revealed similar features and confirmed a consistent phenotypic pattern associated with 2q23.1 
microdeletion. Although this new microdeletion syndrome has certain phenotypic similarities to 
various known disorders such as Angelman, Smith–Magenis, and Rett syndromes, it is not a 
classic phenocopy for any of these conditions.  On the basis of our evaluation of the spectrum of 
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clinical features in our cases and in previously reported ones, we have further delineated the 
clinical characterization of this new microdeletion syndrome. On the basis of the similar features 
observed, we established a clinical characterization of the novel microdeletion syndrome. 
Furthermore, an analysis of all reported cases involving a deletion of 2q23.1 revealed a minimal 
critical region consisting of a single gene, MBD5, as the only deleted gene in one case, and 
MBD5 and EPC2 deleted in all other cases. In this study, we report two new cases of the 2q23.1 
deletion syndrome, describe the syndrome phenotype, define the minimal critical region, and 
analyze the expression of critical region genes toward identification of the causative gene(s) for 
the disorder. 
 
Materials and Methods 
Patient ascertainment  
Subjects were referred for molecular evaluation of the Smith–Magenis syndrome 
(SMS185) and the Prader–Willi syndrome (SMS361). The Institutional Review Boards at 
Virginia Commonwealth University and Michigan State University approved this study.  
 
Cell lines 
Lymphoblastoid cell lines (Epstein–Barr virus-transformed human lymphocytes) from 
SMS185, her mother (SMS184), her father (SMS183), and from an unaffected control were 
cultured in RPMI-1640 with 2 mM L-glutamine and 25 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethane-sulfonic acid) (Invitrogen, Carlsbad, CA USA), 10% fetal bovine serum, and 
1% penicillin/streptomycin antibiotic-antimycotic solution (Invitrogen) at 37oC in a humidified 
5% CO2 chamber. Cells were grown at the same time period for a span of 3 weeks and 
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supplemented with fresh media every 2–3 days as needed. Cells were monitored for growth 
using bright field microscopy and were counted using Trypan blue exclusion with a 
hemocytometer. After a 3-week growth period, the cells were counted, pelleted, and used 
immediately for RNA extraction or stored at -80oC for RNA extraction at a later date. 
 
RNA extraction 
RNA was extracted from either 5–10x106 lymphoblast cells using the standard TRIzol 
protocol (Invitrogen) or from 4 ml whole blood, as described here. The whole blood was mixed 
with 46 ml Puregene RBC lysis solution, mixed, and let to stand at room temperature for 15 min. 
White blood cells were pelleted at 600g for 10min at 41oC. The pellet was resuspended in 1 ml 
RBC lysis solution and incubated at room temperature for 5min. Cells were pelleted at 3000 
RPM at 41oC for 2min resuspended in 1 ml cold PBS, and further pelleted at 3000 RPM at 41oC 
for 2 min. RNA was then isolated using the standard TRIzol protocol (Invitrogen). The 
concentration and purity of RNA were measured at an absorbance of 260 and 280 nm. RNA was 
stored at -80oC until ready for use.  
 
Real-time qRT-PCR 
First-strand cDNA synthesis using SuperScript II RT (Invitrogen) was prepared with 3 
mg of total RNA using Olgio(dT)12-18, and optional RNase OUT treatment, followed by RNA 
degradation with 2.5 units RNase H (Applied Biosystems Inc., Foster City, CA, USA). For 
quantitative real-time PCR, predesigned assays on Demand Gene Expression Products 
(Fermentus, Glen Burnie,MD USA) Taqman MGB probes for MBD5, EPC2, KIF5C, and 
GAPDH were used (Applied Biosystems Inc.). GAPDH was used as the endogenous control. All 
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samples of cDNA were run in triplicate in 10 ml reaction volumes.  Taqman Universal PCR 
Master Mix (Applied Biosystems Inc.), the probe, and deionized water were mixed together in a 
fixed ratio, and 8 ml was added to each well. Diluted cDNA (1:5) was then added to each well. 
PCR conditions were the Standard 7500 Run mode of the ABI Prism 7900 HT Sequence 
Detection System (Applied Biosystems Inc.). The cycle threshold (CT) was determined during 
the geometric phase of the PCR amplification plots, as recommended by the manufacturer. 
Relative differences in transcript levels were quantified using the DDCt method. Acquired data 
were analyzed using 7500 Fast System SDS Software (Applied Biosystems Inc.). 
 
RAI1 sequencing 
RAI1 sequencing was performed as previously described [34] for SMS185. A novel 
familial polymorphism was found, but no pathogenic mutations were identified in this case.  
Peripheral blood was collected, from which DNA was prepared immediately or from cell lines 
established previously. DNA was extracted following standard phenol chloroform methods.   
 
Whole-genome array comparative genomic hybridization (aCGH)  
BAC aCGH was performed as previously described [40, 93].  
 
Oligonucleotide array CGH  
Oligonucleotide-based microarray analysis was performed for SMS361 using a 105K-
feature whole-genome microarray (SignatureChip Oligo Solution made for Signature Genomic 
Laboratories by Agilent Technologies, Santa Clara, CA,USA) as previously described [94]. 
Oligonucleotide-based microarray analyses were performed using a 244K feature whole-genome 
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microarray made for Signature Genomic Laboratories by Agilent Technologies to characterize 
the extent of the abnormalities in SMS185 and SMS361. Genomic DNA labeling was performed 
as described for BAC arrays, whereas array hybridization and washing were performed as 
specified by the manufacturer (Agilent Technologies). Arrays were scanned using an Axon 
4000B scanner (Molecular Devices, Sunnyvale, CA, USA) and analyzed using Agilent Feature 
Extraction software v9.5.1 and Agilent CGH Analytics software v3.5.14. Results were then 
displayed using custom oligonucleotide array CGH analysis software (Oligoglyphix, Signature 
Genomic Laboratories, Spokane, WA, USA).   
 
Fluorescence in situ hybridization (FISH) analysis  
Metaphase FISH was performed using bacterial artificial chromosome (BAC) clone 
RP11–951G8 from the 2q deleted region as previously described [95]. FISH data are shown in 
Figure 12. 
 
RESULTS 
Case reports 
Case 1 (SMS185)  
SMS185 is a 13-year-old Caucasian girl first seen for a clinical genetic evaluation when 
she was 4 years old because of concerns regarding developmental delays, short stature, and 
microcephaly (Figure 10, Table 7). She was the first child of phenotypically normal and 
nonconsanguineous parents (mother 25 years and father 19 years). No remarkable detail of 
pregnancy was mentioned. Birth weight was 3.0 kg and length was 48.26 cm (both between the 
25th and 50th percentile) with no perinatal problems. As an infant, she had significant feeding 
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difficulties due to hypotonia. An atrial septal defect was identified at 1 year of age, with 
spontaneous closure by 3 years of age. By 16 months of age, microcephaly, global 
developmental delays, and short stature were evident. 
A pediatric developmental evaluation was pursued by 3 years for sleep difficulties and 
hyperactivity. The initial physical examination at age 4, 5 and 12 years revealed a weight of 16.1 
kg (50th percentile), a height of 92.25 cm (just below the third percentile), and a head 
circumference of 46 cm (~three SD below the mean). She was quite active, with a hoarse voice 
and no understandable words. Craniofacial examination revealed midface hypoplasia, an 
upturned nose, apparently widely spaced eyes, and a tented upper lip (Figure 10, Table 7). 
Skeletal examination revealed short, thick, and tapered fingers, which measured 9.5, 5.5, and 4 
cm for total hand, palm, and middle finger lengths, respectively (all below the third percentiles). 
X-rays of the hands revealed shortened and widened metacarpals and phalanges in a symmetric 
manner, with no evidence of focally shortened bones. 
Follow-up exam at 9, 3, and 12 years revealed a history of the onset of complex-partial 
seizures at 8 years associated with an abnormal EEG with “mild, diffuse encephalopathy” 
changes noted, but no areas of focal changes or seizure activity. Her brain MRI scan was normal, 
and after beginning trileptal, there was no recurrence of seizure activity. A further evaluation at 
10, 9, and 12 years noted behavioral difficulties related to significant hyperactivity, minimal 
expressive speech, a weight of 33.1 kg (30th percentile), a height of 123.2 cm (approximately 
three SD below the mean), and a head circumference of 50 cm (just below the third percentile). 
Her physical features were unchanged from the initial examination. 
Results of karyotype and FISH analyses to detect a Smith–Magenis syndrome deletion 
were normal at 4 years of age. Sequencing of the RAI1 gene did not reveal any pathogenic  
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Figure 10.  Clinical features of the 2q23.1 deletion syndrome. A) Case 1, SMS185 aged 2 
years. Note tented upper lip, open mouth, and microcephaly. B) SMS185, 13 years of age, note 
tented upper lip and prominent incisors. C) Hands of SMS185, 13 years of age; note 
brachydactyly. D) Case 2, SMS361 aged 8 years. Note tented upper lip with prominent upper 
incisors and open mouth. E) Hand of SMS361. Note generalized brachydactyly. F) Foot of 
SMS361, note small foot and short toes with bulbous tips.
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Table 7.  Clinical features of cases with 2q23.1 microdeletion syndrome.  In part created by Sureni Mullegama. 
 
SMS185 
Case 1, This 
Study 
SMS361 
Case 2, This Study 
Patient 29195 
Wagenstaller et al 
2007 
Patient 1 
Jaillard et al 2008 
Patient 2 
Jaillard et al 
2008 
Patient 3 
Vissers et 
al  2003 
Koolen et 
al 2004 
Patient 2 
De Vries 
et al 2005 
 
PHENOTYPE        
SEX F F M M M F F 
AGES OF EVALUATION 4 & 13 years 3 & 9 years 1.5 years 2 & 10 years 3 & 10 years 2, 12 &14 
years 
N/A 
MENTAL RETARDATION + + + + + + + 
MOTOR DELAY  + + + + + + + 
LANGUAGE IMPAIRMENT Severe 50 words + Less than 6 words Severe Severe N/A 
BEHAVIORAL PROBLEMS + 
Hyperactivity 
+ 
Social contact 
seeking 
behavior 
Hyperactivity 
Impulsiveness 
+ 
Limited social 
interactions 
+ 
Inappropriate laughter 
 
+ 
Inappropriate 
laughter 
Autistic 
component 
Self-biting of 
hands/forear
m 
Decreased 
sensitivity to 
pain 
Stereotypies 
N/A + 
Picking of 
the eyes 
Hypernea 
Full hands 
into mouth 
SHORT ATTENTION SPAN + + N/A + N/A N/A N/A 
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SLEEPING DIFFICULTIES + - N/A - + N/A N/A 
POST-NATAL GROWTH 
RETARDATION 
+ - N/A + + + + 
SHORT STATURE + + N/A - - + + 
SEIZURES + + + + + + + 
ATAXIA - + N/A + + N/A N/A 
FEEDING DIFFICULTIES + + N/A + + N/A N/A 
INFANTILE HYPOTONIA + + N/A + + N/A N/A 
CONSTIPATION + + N/A + + N/A N/A 
 
CRANIOFACIAL 
MANIFESTATIONS 
+ +  + + + + 
 MICROCEPHALY + 15% N/A + + + + 
 BRACHYCEPHALY - - N/A - + - - 
 MIDFACE 
HYPOPLASIA 
+ + N/A - + - - 
 HYPERTELORISM +/- 
Apparently 
widely-spaced 
eyes 
- N/A + - N/A N/A 
 FLAT NOSE - - + + - Small nose N/A 
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 WIDE MOUTH + + + + + N/A + 
 TENTED UPPER LIP + + N/A + + N/A N/A 
 OPEN MOUTH + + + + + N/A N/A 
 SMALL CHIN - + N/A + + - - 
 DENTAL ANOMALIES + + N/A - + + N/A 
 MACROGLOSSIA - - N/A - + - - 
EYE FINDINGS  Optic nerve 
hypoplasia 
Mild myopia 
30% right 
intermittent 
esotropia 
 Hypermetropia 
Astigmatism 
   
HAND/FOOT 
ABNORMALTIES 
+ + + + + + + 
 5TH FINGER 
CLINODACTYLY  
- + N/A - + + + 
• BRACHYDACTYLY  - 
Small hands and feet 
- 
Small hands and feet 
N/A - + N/A N/A 
OTHER   
Lumbar lordosis 
Toes bulbous at 
tips 
Bitemporal 
narrowing 
Relative obesity 
Hypoactive 
Sandal gap 
Micropenis 
Scoliosis 
Valgus feet 
Recurrent ear 
infections 
Calm 
baby 
Hypogen
italism 
Pseudoar
throsis 
of the 
clavicle 
 
Sandal gap 
Large ears 
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mutations (data not shown).  DNA methylation for the Angelman syndrome was normal at 9 
years.   
 
Case 2 (SMS361) 
SMS361 is a 10-year-old Hispanic girl who was first seen at 26 months of age for 
developmental delay (Table 7). She was born to an 18-year-old gravida 1 mother. She was 
thought to have Down syndrome at birth, but chromosome testing was negative by report. Her 
family history was unremarkable. 
She had a generalized tonic-clonic seizure at 8 months of age, but her EEG and CT scans 
were normal. She was treated with valproic acid and has had only 1–2 seizures/year. At 4 years 
of age, a repeat EEG showed spike and wave epileptiform discharges from the frontal lobes.  
This pattern has been observed on and off during successive EEGs, with the latest EEG at 7 
years of age demonstrating a left-sided spike and wave pattern from the left frontal lobe. Several 
brain MRIs were normal.  She walked after 2 years of age. Her speech was delayed, but she did 
learn new words. At the age of 2 years and 11 months, she knew about a total of 50 words in 
English and Spanish. She did not start putting two words together until after 9 years of age. Her 
speech was unclear, although she continues to add words to her vocabulary. She can follow 
simple commands, but her attention span is limited. 
A physical examination at 9 years of age showed truncal obesity, with a height of 122 cm 
(5th percentile), weight of 41.0 kg (90th percentile), and an occipitofrontal circumference of 50.5 
cm (15th percentile). She was hyperactive, impulsive, and had a short attention span, moving 
from object to object in the examination room 
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(Table 7). She had social contact-seeking behavior, maintained good eye contact, and had a 
happy demeanor. She had an unusual facial appearance with a tented upper lip and bitemporal 
narrowing. She had light-colored irides. Her hands were small (total hand length of 13 cm, less 
than third percentile) and showed clinodactyly of the fifth digits (although her hand X-ray 
showed no shortened fourth metacarpal).  Her total foot length was 17.5 cm (less than third 
percentile) and the toes were bulbous at the tips (Figure 10). Ophthalmologic examination 
revealed mild optic nerve hypoplasia, mild myopia, and a 30% right intermittent esotropia. Her 
caregiver reports a healthy appetite but no food seeking was described. 
 
Molecular analyses 
aCGH 
Array comparative genomic hybridization: SMS185 was evaluated by whole-genome 
array comparative hybridization (aCGH BAC array) [96], revealing a ~700kb deletion of 2q23.1 
and confirmed by a clinical BAC array (data not shown). To further refine the break points of 
this deletion, a high-resolution oligo array (Agilent 244K) was performed, defining the deletion 
region to be ~930 kb at chr2:148,447,496–149,377,297 (NCBI36/hg18 coordinates, Figure 11), 
encompassing four known genes, ORC4L, MBD5, EPC2, and KIF5C.  SMS361 was evaluated 
by both 105K and 244K oligo arrays (Figure 11), as described in the methods section.  
Array data revealed a 3.51-Mb deletion of chromosome 2q22.3–q23.3 
(chr2:146,798,229–150,310,317, NCBI36/hg18 coordinates) encompassing nine known or 
predicted genes, PABPCP2, ACVR2A, ORC4L, MBD5, EPC2, KIF5C, LYPD6B, LYPD6, and 
MMADHC. 
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Figure 11.  Array analysis of individuals with microdeletions of 2q23.1. A, B) 
Oligonucleotide microarray profiles for (a) a single-copy loss of 930 kb at chr(2)(q23.1); 
(chr2: 148,447,496–149,377,297) in SMS185 and (b) a single-copy loss of 3.51 Mb at 
chr(2)(q22.3-q23.3) (chr2: 146,798,229– 150,310,317) in SMS361. For microarray plots, 
probes are ordered on the x axis according to physical mapping positions, with distal 2p to the 
left and distal 2q to the right. C) Summary of the deletion sizes in individuals with 
microdeletions encompassing 2q23.1. Green bars indicate the minimum deletion sizes in 
individuals in this study and those in the literature, and black lines extend to show maximum 
deletion sizes. Genes in the region are indicated by blue boxes. Coding exons for MBD5 are 
included in the solid blue box, whereas 5’ noncoding exons described by Wagensteller et al 
[1] are within the dashed blue box.  Modified from Williams et al. 2009 [2].  Arrays 
performed by Signature Genomics. 
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Metaphase FISH with RP11–951G8 confirmed a deletion in five out of five cells 
examined for both SMS185 and SMS361 (Figure 12). Array data indicate a common, 
overlapping region between these two cases that includes ORC4L, MBD5, EPC2, and KIF5C 
(Figure 11). 
 
Quantitative real-time PCR  
Loss of genes or gene function due to chromosomal deletion does not necessarily 
correlate to a reduction in gene expression; however, haploinsufficiency of one or more genes is 
typically the pathological defect in microdeletion syndromes. To determine the genes that have a 
reduced expression in the overlapping 2q23.1 region, both subjects were assessed for MBD5, 
EPC2, and KIF5C mRNA levels in white blood cells.  Correlating directly to the confirmed 
deletions, both SMS185 and SMS361 have an ~50% reduced expression of MBD5 and EPC2 
mRNA compared with normal controls (Figure 13). 
Normal levels of expression were observed for KIF5C; however, KIF5C has a very low 
expression in peripheral blood, and thus, levels may not be reflective of the expression in the 
brain (data not shown). KIF5C expression may be affected in both the larger and smaller deletion 
cases, as the smaller deletion includes the 5’ region of the KIF5C gene, which may alter gene 
expression.  The reduction in expression of MBD5 and EPC2 supports the potential role of each 
of these genes in the pathophysiology of this disorder. 
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Figure 12.  FISH confirmation of 2q23 deletions in patients SMS361 (A) and SMS185 (B).  
for both images, BAC clone RP11-951G8 from 2q23.1 is labeled in red and a chromosome 2 
centromere probe is labeled in green as a control.  The red signal is missing, while the green 
signal is retained on one chromosome 2 homologue, indicating a deletion.  Performed by 
Signature Genomics.  
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Figure 13.  Quantitative real-time PCR expression analysis of MBD5 and EPC2 in patient 
cells. MBD5 and EPC2 relative gene expressions in SMS185 (EBV-derived lymphoblastoid cell 
line) and SMS361 (fresh white blood cells) are shown. Gene expression is shown relative to 
GAPDH expression and control cells, with relative expression values based on the ∆∆Ct value 
with normal control set to 1. Control cells were cultured or isolated at the same time and with the 
same methods as test cells. All experiments were performed in triplicate and average values for 
all combined experiments are shown (n=2–5).  Data generated, in part, by Sureni Mullegama.  
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DISCUSSION 
In this study, we present two subjects, SMS185 and SMS361, with a del(2)(q23.1). These 
individuals have a distinct clinical phenotype that includes severe cognitive impairment, 
seizures, relative obesity, small hands and feet, and mild craniofacial dysmorphism, including 
one child with microcephaly. 
A recent report described two patients with overlapping deletions of this region on 
chromosome 2 exhibiting a ‘pseudo-Angelman’ phenotype [64]. Both the subjects in this study 
tested negative for an abnormal SNRPN DNA methylation patterning of the 15q11.2 region, 
which rules out a diagnosis of Angelman syndrome. However, they do have features consistent 
with the ‘pseudo-Angelman’ phenotype described by Jaillard et al (2008) [64].  In addition to the 
report by Jaillard et al (2008) [64], three other cases of 2q23.1 deletion have been previously 
described [70, 91, 92] (Figure 11). The common phenotypes observed in these subjects are 
severe mental retardation, motor delay, severe language impairment (sometimes accompanied by 
hoarse voice), behavioral abnormalities (including hyperactivity and inappropriate laughter), 
postnatal growth retardation, relative obesity, and seizures (Table 7). In addition, a distinctive 
craniofacial phenotype is also apparent that includes small head size, wide and open mouth, a 
tented upper lip, and prominent incisors (Figure 10). Skeletal abnormalities include generalized 
brachydactyly (Figure 10, Table 7). 
The more variable phenotypes between the cases reported here and those in previous 
studies include craniofacial abnormalities such as brachycephaly and relative hypertelorism 
(likely associated with microcephaly), as well as eye findings and genital abnormalities.  Overall, 
these individuals with varying overlapping deletions of 2q23.1 present with a very similar global 
phenotype, which leads us to believe that a common gene(s) might be involved.   
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Additionally, after completion of this study a study by van Bon et al. 2010 [97] 
confirmed the findings reported in the present study.  All subjects fell within the global 
phenotype described and it was concluded that haploinsufficiency of MBD5 was responsible for 
the clinical manifestations observed.  It was also mentioned that EPC2 and KIF5C are likely 
modifiers of overall variability [97].   
It is worthwhile to mention that reported duplications of the 2q23 region are rare and tend 
to be much larger in size than the deletions described in this and previous reports [98, 99, 100]. 
The reported duplication 2q23 cases presented with craniofacial abnormalities, low set ears, and 
heart, kidney, genital, skeletal, and neurological abnormalities, with death resulting in early 
infancy [101]. The phenotype observed in dup(2)(q23) further supports a gene dosage as a 
mechanism and the importance of the genes in this region.  When considering all of the reported 
deletions involving 2q23.1 (Figure 11), a critical region emerges that includes a single gene, 
MBD5.  MBD5 (methyl-CpG binding domain protein 5) is expressed neuronally and likely 
functions in the regulation of gene expression [102, 103]. MBD5 contains a methyl-binding 
domain, sharing sequence homology to MECP2, which when mutated or deleted, results in Rett 
syndrome. We have shown in this study that MBD5 is haploinsufficient in patient white blood 
cells and lymphoblastoid cells (Figure 13), providing further evidence of its role in this 
syndrome and the need for proper gene dosage for normal development and behavior. We do not, 
however, rule out the possibility that KIF5C and/or EPC2 may contribute to variability or 
severity of the syndrome.  These data, taken together with the previous report of a small deletion 
within MBD5 [1, 64] and the recent study by van Bon et al. [97], indicate that haploinsufficiency 
of MBD5 is the likely common pathological defect for most features of this syndrome. 
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Chapter 4 
Haploinsufficiency of HDAC4 results in brachydactyly mental retardation 
syndrome 
 
Introduction 
Chromosome deletions involving the 2q37 region result in brachydactyly mental 
retardation syndrome (BDMR, OMIM 600430), also known as Albright hereditary 
osteodystrophy-like syndrome (AHO-like).  BDMR is a complex disorder that presents with a 
spectrum of clinical features, including developmental delay, autism spectrum disorder, 
craniofacial and skeletal abnormalities, cardiac defects, behavioral problems, and neurological 
anomalies.  Approximately 100 individuals have been reported with a deletion involving the 
chromosome 2q37 region [83].  To date, the critical region for this syndrome has not been clearly 
defined, and a variety of phenotypes have been mapped to the 2q37.1→2qter region [83].  
Variable expressivity and reduced penetrance for most major features complicate 
genotype:phenotype correlations in this syndrome and further impair diagnosis. 
In a study of 52 individuals referred for a phenotype consistent with Smith-Magenis 
syndrome (SMS) but for whom no 17p11.2 deletion or RAI1 mutation could be found, we 
identified by whole genome array comparative genomic hybridization (aCGH) several copy 
number variants responsible for the SMS-like phenotypes observed in these individuals [96].  
Interestingly, we identified 2 cases that carried overlapping deletions of the 2q37 region [96].  
After a literature review, we discovered that the phenotypic overlap between these two distinct 
syndromes was striking.  Utilizing this unique aCGH data set and additional cases, we refined 
the critical region for BDMR, reducing the likely candidates to a single gene, HDAC4.  Given 
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the apparent phenotypic overlap between SMS and BDMR, we then investigated more closely 
the specific phenotypes in our cohorts with Smith-Magenis syndrome-like and/or AHO-like 
features and identified one subject who lacked a 2q37 deletion but had striking phenotypic 
overlap with known 2q37 deletion cases.  Sequencing of the coding region of HDAC4 in this 
case revealed a de novo single base insertion that truncates the protein.  HDAC4 (histone 
deacetylase 4) is known to be critical for proper skeletogenesis and chondrogenesis [104], as 
well as neuronal survival [105].  Taking into consideration the overlapping deletion data and de 
novo mutation presented here, we assert that haploinsufficiency of HDAC4 results in the 
brachydactyly mental retardation syndrome.       
 
Materials and methods 
Subject ascertainment 
Subjects were referred to the Elsea laboratory for molecular evaluation of SMS at 
Michigan State University, or Virginia Commonwealth University, or to the Aldred Laboratory 
at the Cleveland Clinic for AHO-like phenotype.  Samples and medical records were collected in 
accordance with Institutional Review Board approved protocols from the appropriate institution.  
Peripheral blood was collected, and DNA and metaphase chromosomes were prepared following 
standard methods.  Phenotypic information was collected from medical records, geneticist 
reports, and patient photos.  
Genomic DNA sequence analysis 
Total DNA was isolated from cultured peripheral white blood cells using the QIAamp 
DNA Minikit (QIAGEN, GmbH, Hilden, Germany).  PCR was performed using intronic primers 
from the HDAC4 gene generated using Primer3 (v. 0.4.0) (http://frodo.wi.mit.edu/primer3/), 
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which flank both the 5’ and 3’ regions of each HDAC4 exon (Table X).  PCR products were 
treated with ExoSAP-IT (USB, Cleveland, OH) to digest PCR primers.  Sequencing and analysis 
of electropherograms were done as previously described [54].  PCR products were sequenced 
and analyzed on both the forward and reverse DNA strands.  Sequencing primers are provided in 
the Tables 8, 9. 
 
Multiplex ligation-dependent probe amplification and SNP array analysis 
MLPA was performed as previously described [106] using five custom-designed probe 
sets that were approximately equally spaced across the genomic extent of HDAC4 (Table 10).  
Breakpoints outside of the HDAC4 gene were defined using Illumina CNV370 single nucleotide 
polymorphism arrays and Beadstudio software to identify copy number changes. 
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Table 8.  HDAC4 amplification and sequencing oligonucleotides. 
Exon Primer Primer Sequence Tm (C) Amplicon 
1 1F GGCTCGGCGCTTGAACGTCT 64 220 
1 1R TGGGCAAAGAAAGCCCCGCT 64  
2 2F TGCGCGCAGTTTCTGAAGCC 64 214 
2 2R CCCCTCGCCCTCTCTGCACT 64  
3 3F CCAGGGACAGCAAAGGGCGG 66 376 
3 3R CGGAGGCAGGGCTGGAGTCA 66  
4 4F AGCCCGGAATGGCCCTGACT 63 654 
4 4R TACTCCCCGTGTGCTGCCCC 63  
5 5F TAGCCGTCCCCAGCCCTTCC 64 412 
5 5R CTGCCGCACGAGTGTACCCC 64  
6 6F GGGGCAGTGCGCTGGGTAAA 64 285 
6 6R CTGCAGGTGATTCCTTCTCTAAGTGG 64  
7 7F TGAGCTCCCTGCGCTCTCCC 64 400 
7 7R GGGGGTTGACAGCGTGAGGC 64  
8 8F GGGCATTCGGGCCACAGGTC 64 320 
8 8R AGGCCACTTTCCCTCACCCCA 64  
9 9F ATGTTTGGCCGTGACAGACT 60 219 
9 9R AAGGACCCATCACCACCAC 60  
10 10F AGCATCCTGGCTGTGCTTT 58 242 
10 10R CCAGGCCCATTTGTGCTC 58  
11 11F TTCCCCTCTGCTGTTTCTTC 58 398 
11 11R GTTCCCTCTTTCTGCCTCCT 58  
12 12F GACCCAGCTCTCTGTGCTTC 60 377 
12 12R ACCACAGAAGATGCCACCTG 60  
13 13F CAACACGGCCGTTTCTTC 60 243 
13 13R ACCCTCAGGCTGCACAAA 60  
14 14F ATGACACGCTGATGCTGAAG 58 237 
14 14R TAAGCCCAAAGAACCACCTG 58  
15 15F CTGTCTGTGGAGCTGAAGCA 60 222 
15 15R ACCCAATATGGGAGGAAAGG 60  
16 16F CCTCGTTGTCCCACAAATG 58 220 
16 16R ACCACTGGGACTCGAGAAGA 58  
17 17F TCACTGTGGGGTGTTGTTTC 58 232 
17 17R CAGCCTGATGAGAGGGAGAC 58  
18 18F AGGGTGCAGCAAGAAACTGT 58 245 
18 18R CCTAAGGGAGGGAAGGAAGA 58  
19 19F CTCCAGCGTCAGTTCTCTCC 60 223 
19 19R CCTAAGCTTCCCACATCCAA 60  
20 20F TGCCTCAGCCCTGAAGTAGT 60 179 
20 20R GGCCCTTATATACCCCACCT 60  
21 21F CGTGTGTTTCTCTCCTTCTGG 60 215 
21 21R GACACGCTCATCTCCAACAA 60  
22 22F ACCCAGTAACGCCTTCTCCT 60 234 
22 22R TAAAAAGGGGACCTGACACG 60  
23 23F TCTTACGATGCCATGAGACG 60 242 
23 23R GGGTCTCTGGGGTCTTCCTA 60  
24 24F GTCTCGGAACACCCGTCTAA 60 240 
24 24R GTATAGGGGGACAGGGATGG 60  
25 25F ACTTTCCTCACCCCACCAC 60 246 
25 25R GGTTCTGACCCTGAATAGTGTG 60  
 67 
26 26F CACAGCCTTTAACCCACGTT 60 183 
26 26R TGGCTGAGCTTCAAGACAGA 60  
 
 
 
  
Table 9.  HDAC4 cDNA oligonucleotides for amplification and sequencing. 
Coding exon 
(cDNA) Primer Sequence Tm 
Amplicon 
(bp) 
1-8 cDNA 1F GAGTTTGGAGCTCGTTGGAG 56 1135 
1-8 cDNA 1R AAGGATGGCGATGTGTAGAGG 56  
1-8 Sequencing Primer 1F GCAGCTCAAGAACAAGGAG NA NA 
1-8 Sequencing Primer 1R CTCTTTGCCCTTCTCCTTGTTC NA NA 
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Table 10.  MLPA probes for 2q37.3 and HDAC4.  Designed by Dr. Michaela Aldred 
Name Sequence 
Ensembl  
Build 41 
rs870790A GGGTTCCCTAAGGGTTGGATTCTTAGGACCTGAAAGTCTGAACCAGCATTCCAA 239980739 
rs870790B GTGGGAGTATTGTTCAAGCGGTGATGGAATTGTCTAGATTGGATCTTGCTGGCAC 239980805 
HDAC4-
2A GGGTTCCCTAAGGGTTGGAGAGGCTCGGCGCTTGAACGTCTG 239939431 
HDAC4-
2B TGACCCAGCCCTCACCGTCCCGGTACTCTAGATTGGATCTTGCTGGCAC 239939479 
HDAC4-
3A GGGTTCCCTAAGGGTTGGATGGCCGAGACCAGCCAGTGGAGCTG 239823237 
HDAC4-
3B CTGAATCCTGCCCGCGTGAACCACATTCTAGATTGGATCTTGCTGGCAC 239823287 
HDAC4-
i9A GGGTTCCCTAAGGGTTGGAGCACTTGCCCTTCACTCTTCACCTTCCA 239726184 
HDAC4-
i9B ATTTGGGGTGAGGGAAAGTGGCCTGTGTCTAGATTGGATCTTGCTGGCAC 239726238 
HDAC4-
i26A GGGTTCCCTAAGGGTTGGACTCCTTCCAGTGCCAAAGCCCCTTAGAGAC 239639900 
HDAC4-
i26B GCATGAGGAGCATTAGATCCTGAACAGATGGATCTAGATTGGATCTTGCTGGCAC 239639961 
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Results 
Utilizing recent studies of SMS-like [96] and known deletion 2q37 subjects [107], we 
were able to make genotype:phenotype correlations allowing refinement of the critical region for 
BDMR to ~chr2: 239,639,900-240,938,547 within the 2q37.3 band, including the HDAC4 gene. 
 
BDMR clinical phenotype 
 The deletion 2q37 syndrome phenotype consists of a variety of findings that overlap with 
other syndromes such as Smith-Magenis, Prader-Willi, Angelman, and fragile-X syndromes 
(Table 11).  Common features include mild facial dysmorphism, congenital heart defects, distinct 
brachydactyly type E, intellectual disabilities, developmental delay, seizures, autism spectrum 
disorder, and obesity [83, 107].  Genotype:phenotype correlations have been attempted in the 
past but have failed to identify a single gene that may contribute to the core findings observed in 
BDMR. 
Deletion cases we previously reported showed the classical BDMR phenotype (Table 11).  
SMS272 is obese Native American with cognitive and developmental delays and was originally 
referred for features of Smith-Magenis syndrome (SMS).  Skeletal features include 
brachydactyly type E (shortened 3rd, 4th, and 5th, metacarpals with shortened and proximately 
paced 4th left toe), midface hypoplasia, and brachycephaly (Figure 16, Table 11).  She also 
exhibits stereotypies and aggressive behavior but lacks two of the key features, sleep disturbance 
and self-abusive behavior, which are common in SMS.  She carries a small, 1.17 Mb, 2q37.3 
deletion which was later confirmed on karyotype (Figure 14).   
SMS320 was referred for developmental, speech, and motor delays, sleep disturbance, 
stereotypies, attention-seeking, and self-injurious behaviors. Her craniofacial and skeletal 
 70 
phenotype consists of brachydactyly, brachycephaly, midface hypoplasia, tented upper lip, and a 
broad, square face (Table 11).  While originally referred for SMS, she carries a larger deletion of 
2q37.3 that spans 3.02 Mb (Figure 14). 
Subject 122 presented with developmental delay, mild facial dysmorphism, BDE and 
receptive language and social communication disorder. A detailed clinical description was 
published previously [107].  Case 122 carries a 3.21 Mb 2q37 deletion (Figure 14). 
Subject 10780, who carries a 3.2 Mb deletion within 2q37 (Figure 14), presented with, 
developmental delay, short stature, facial dysmorphism, brachydactyly type E, and grand mal 
seizures (Table 11).  A detailed clinical description has been published previously [71] 
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Table 11.  Clinical features of cases with deletions or mutations involving 2q37.3. 
PHENOTYPE 
SMS117 
HDAC4 mutation 
SMS272 
del(2)(q37.3) 
including HDAC4 
[96] 
SMS320 
del(2)(q37) 
including 
HDAC4 [96] 
122 
del(2)(q37) 
including 
HDAC4 [107] 
10780 
del(2)(q37) 
including HDAC4 
[71] 
2282 
del(2)(q37.3) 
not including 
HDAC4 
Sex F F F F F F 
Age at evaluation 16 and 25 years 15 and 17 years 3 years 6 years 12 years 7 years 
Developmental delay + + + + + + 
Motor delay  + - + + + + 
Language impairment + + + + + + 
Behavioral problems 
 
Self-injurious behavior 
Pulling out of 
fingernails 
Aggressive behavior 
Hand wringing 
Eye squint 
 
Self-injurious 
behavior 
Head banging 
Skin picking 
Hand biting 
Hyperactivity 
receptive language 
and social 
communication 
disorders N/A 
Autistic behavior 
Repetitive 
behaviors 
Stereotypies  
 
 
Self-hug, tics 
 
Self-hug N/A N/A N/A 
 
Sleeping difficulties + - + N/A N/A N/A 
 
Decreased sensitivity 
to pain 
 + + + N/A N/A N/A 
Hearing loss +  - - - - 
Short stature +/- - - + + - 
Seizures essential tremor - - - + + 
Feeding difficulties + - - - N/A - 
Obesity/overweight + + + - - + 
 
Craniofacial 
manifestations 
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Broad face + + + + + + 
Upslanting     eyes + + + - -  
Brachycephaly + + +    
Midface hypoplasia + + +  + + 
Broad, upturned 
nose + + +  + - 
 
Skeletal abnormalities  
      
Brachydactyly  +, type E +, type E - + + - 
 
Proximally placed 
4th toe, shortened 
4th metatarsal + + - + + - 
OTHER 
Subvalvar aortic 
stenosis; mitral 
stenosis; pacemaker 
Hypothyroidism 
Hirsuitism 
Spina bifida occulta 
Very friendly 
Sinus arrhythmia 
Myopia 
Very friendly  2-3 toe syndactyly Craniosynostosis 
Hypothyroidism 
Precocious 
puberty 
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H 
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Figure 14.  Skeletal anomalies observed in BDMR.  A) Hands of case SMS117.  B) Feet of 
SMS117, showing shortened 4th metatarsal and wide spacing between toes.  C) Radiograph of 
left hand of SMS117 showing shortened 3rd, 4th, and 5th metacarpals. D) Radiograph of 
SMS117 feet showing proximally placed and shortened 4th metatarsal and bilaterally widely 
spaced 1st, 2nd, and 3rd toes.  E).  Photo of SMS272 at 17 years of age.  F) Hands of SMS272.  
Note shortened 3rd and 4th fingers.  G) Feet of SMS272 with shortened 3rd toes and proximally 
placed and shortened 4th toes.  H) Radiograph documenting shortened 3rd and 4th metacarpals in 
the hands of SMS272.  
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 Refinement of the BDMR critical region 
Refining the critical region for deletion 2q37 syndrome has proven difficult because of 
poor genotype:phenotype correlation and a paucity of interstitial deletions that would help define 
minimal overlapping candidate regions.  However, because of deletions identified within a small 
overlapping region within the 2q37.3 band [96, 107], we were able to narrow the critical region 
to ~200 kb region including HDAC4 (Figure 14), with SMS272 critical to this analysis due to the 
very small deletion identified by aCGH.  Further supporting the refinement of this region to ~200 
kb is subject 2282 who does not have the BDE phenotype  However this patient does have 
developmental delay, facial dysmorphism and autistic behaviors (Table 11), indicating that other 
aspects of 2q37 deletion syndrome are complex and like many deletion/mutation syndromes 
multiple genes may contribute to the full spectrum of the phenotype. 
Two del(2)(q37.3) subjects were analyzed by MLPA to assess the specific location of the 
break points observed (Figure 15, Table 10 ).  As shown in Figure 15 , the proximal breakpoints 
of the deletions are within the HDAC4 gene.  The breakpoint identified in case 122 is in the 
second intron of HDAC4, while the breakpoint for case 10780 is in intron 9 (Figure 15).  Both 
deletions should result in haploinsufficiency for HDAC4 as the promoter and initial coding exons 
are deleted in both cases (HDAC4 is transcribed on the minus strand of DNA).  These two 
subjects have a strikingly similar phenotype to that of SMS117 and to other BDMR cases, 
including intellectual disabilities, developmental delay, brachydactyly type E, and facial 
dysmorphism.  Case 10780 also has short stature with obesity, further strengthening the case for 
mutations in HDAC4 to contribute to the core phenotypes of BDMR. 
Further supporting the notion that deletion of HDAC4 is responsible for the 
brachydactyly type E phenotype, subject 2282 has a 2.68 Mb terminal deletion with a breakpoint 
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that is distal of HDAC4 (Figure 14).  This individual presented with developmental delay, 
obesity, autistic behaviors and a history of seizures but had no evidence of metacarpal or 
metatarsal shortening.  Facial dysmorphism included a broad face with bi-temporal narrowing 
and small nose with flat nasal bridge.  There was no evidence of heart or other major organ 
defect.  An additional case, subject 2232, was diagnosed with a terminal 2q37 deletion 
approximately 7 Mb in size (Figure 14).  Unfortunately no clinical details were available and 
thus this case is not included in Table 11. 
These molecular and clinical data supported mutation analysis of HDAC4 as the logical 
next step toward identification of a single gene that, when mutated, results in BDMR.  Further 
supporting sequence analysis of cases with the BDMR phenotype but without 2q37 deletion is 
the Hdac4-/- mouse [104], which has a significant skeletal phenotype [104].  Although important 
in electron transport, NDUFA10 was eliminated as a probable cause for BDMR.  
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Figure 15.  Delineation of the BDMR critical region.  A) Ideogram of chromosome 2 band 
q37.3.  B) Schematic representation of 2q37.3 region and RefSeq Genes included 
(www.genome.ucsc.edu, accessed Feb. 25, 2010).  C) Horizontal bars indicate the regions of 
deletion in each of these key 2q37 deletion syndrome cases.  The brachydactyly mental 
retardation syndrome critical region is indicated by the vertical bars.  The SMS117 HDAC4 point 
mutation is indicated by the small red vertical line.  
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Figure 16.  MLPA analysis of HDAC4 deletion breakpoints in key 2q37.3 deletions.  
Top:  Analysis of patient 10780 showed an HDAC4 deletion extending at least through 
intron 9 but the breakpoint occurring prior to intron 26.   Bottom:  Patient 122 revealed a 
deletion including intron 1 and exon 2, with the breakpoint occurring between the probes 
for exon 2 and exon 3.  Stars indicate regions between which the breakpoint occurs for each 
case.  Control probes are indicated by the arrows and show 2 alleles of equal intensity for 
each.   
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SMS117 Clinical phenotype 
SMS117, who is deletion 2q37 negative, is a female French-Canadian born at 43 weeks 
to nonconsanguineous parents (Figures 16, 17 Table 11).  Birth was complicated by two 
induction attempts.  Weight at birth was 2.85 kg (10-25%), and length was 51 cm (25-50%).  The 
1st year was marked with feeding difficulties. Subvalvular aortic stenosis was identified at 4 
months.  Psychomotor development was delayed, with walking at 18 months, and speaking in 
sentences at 6 years of age.  The clinical phenotype worsened with age.  She received a mitral 
valve replacement and permanent pacemaker at 5 years.  At 13.5 years, she was referred to 
genetics where she presented with dysmorphic features, including midface hypoplasia, broad 
face and nose, brachycephaly, frontal bossing, a down turned lower lip, and upslanted eyes.  At 
25 years, physical exam revealed obesity (96 kg, >95%; 157cm, 10-25%).   Neurologically, 
decreased deep tendon reflexes, and cerebral atrophy were also observed, as well as 
sensorineural hearing loss (>40 dB) for which she wears two hearing aids.  Cerebral atrophy was 
identified by head CT, and spina bifida occulta was also observed.  Decreased sensitivity to pain, 
onychotillomania, hyperactivity, and a decreased attention span were also observed, in addition 
to a hospitalization for hypersomnolence and precipitous loss of consciousness.  Sleep 
abnormalities began at 3 years of age with several arousals throughout the night, which lasted 
until the age of 8; however at 24 years, she can sleep for up to 18 hours if not awakened.  A 
complete absence of REM sleep as per 44 hours of EEG video telemetry was noted.  Skeletal 
features include brachydactyly type E with proximally placed 3rd, 4th, and 5th  fingers (shortened 
3rd, 4th, and 5th metacarpals on X-ray) and bilateral proximally placed 4th toes and bilateral 
widely spaced 1st, 2nd, and 3rd toes (Figure 16).  Total hand length was 14 cm (<3%) and total 
foot length was 22.5 cm (10-25%).  There is a striking similarity between the morphology of the 
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hands and feet of SMS117 (HDAC4 mutation) and SMS272 (2q37 deletion) (Figure16), lending 
further support to the importance of HDAC4 in this syndrome.   Family history was 
unremarkable; however, the patient's father died at age 50 years of a pulmonary embolism, and 
no other abnormalities were reported.  
 
Mutation analysis 
 All coding exons for HDAC4, in SMS117, were sequenced and assessed for mutation 
(PCR primers found in Table 8).  When analyzing the nucleotide sequence for exon 19, an 
insertion of a single cytosine was observed (c.2399_2400insC; Figure 17).  Because this 
insertion lies within a run of five cytosines, the exact location of the insertion cannot be 
determined, but this does not impact the resulting location of the premature stop codon 
(Gly801TrpfsX1) (Figure 17). 
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Figure 17.  SMS117 HDAC4 mutation and impact on HDAC4 protein.  A) SMS117 at 13 
years. B) Electropherogram trace showing nucleotide insertion of a single cytosine at c.2399 in 
the HDAC4 gene.  C) Partial amino acid alignment of the normal HDAC4 protein with the 
altered protein likely produced in SMS117 due to frame shift mutation.  Premature stop codon 
highlighted in yellow.  The histone deacetylase domain resides at amino acids 655-1084 (Blue 
line), and the nuclear export signal is at amino acids 1051-1084 (Orange line).  The mutation 
disrupts the HDAC domain and removes the nuclear export signal 
 
 
 
 
 
c.2399_2400insC  A B 
C 
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Discussion 
We describe five individuals with del(2)(q37.3) four of which include or interrupt the 
HDAC4 gene, as well as one individual with a HDAC4 insertion which results in a frame shift 
and truncated protein.  Additional cases from the literature supporting this conclusion include 
patient 2 from Shrimpton et al (2004) with BDE, short stature and cognitive delay and a recent 
report of a patient with BDE, developmental delay, autism and seizures Felder et al, 2009.  
Although HDAC4 was not specifically examined in these two cases, the breakpoints mapped in 
close proximity to HDAC4 suggesting this gene was likely disrupted.  Taken together, we 
conclude that haploinsufficiency of HDAC4 results in brachydactyly mental retardation 
syndrome.  
 
HDAC4 
HDAC4 is a class II HDAC which acts as a co-repressor for DNA-binding transcription 
factors.  Acting in concert with HDAC9 and HDAC3, HDAC4 acts to inhibit a variety of 
transcription factors including, MEF2C and RUNX2, and serves to deacetylate histones, both of 
which are essential for proper skeletal development.  This deacetylation condenses chromatin 
making it inaccessible to factors that drive transcription.  Additionally, class II HDACs are 
antagonists of cardiac hypertrophy needed for proper cardiac development [108].  Because of 
this molecular evidence it is logical to conclude that deletion or mutation of HDAC4 would lead 
to the core phenotypes seen in BDMR. 
 
HDAC4 mutation 
The impact of this insertion, found in SMS117, on the HDAC4 protein is significant.  The 
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premature stop codon interrupts the histone deacetylase domain potentially limiting or 
preventing all histone deacetylase activity from this HDAC4 allele.  This deacetylase activity is 
essential for protein function, as HDAC4 has the ability to deacetylate all four core histones 
[109].  Fischle et al. [110] showed that if amino acids 1002–1058 or 803-846 of HDAC4 (the 
most conserved domain of HDAC4 across species) are deleted, interaction with HDAC3 and all 
histone deacetylase activity are eliminated.  As shown in Figure 17, the insertion of a cytosine at 
codon 801 causes a frame-shift that significantly reduces amino acid identity (5%) or similarity 
(5%) between the SMS117 mutant and wild type alleles.  Taken together, these data provide 
evidence that the mutant HDAC4 protein is completely void of histone deacetylase activity and 
can no longer bind with HDAC3.   Further, when mutated from histidine to alanine, a charged 
polar to nonpolar change at p.802 and p.803, Fischle et al. showed that binding to N-CoR was 
eliminated [110].  N-CoR is essential for HDAC3 recruitment and HDAC activity of the 
complex.  The SMS117 mutation of HDAC4 shows a p.H802T, and p.H803P change at these 
essential amino acids leading to charged polar to uncharged polar and charged polar to nonpolar 
changes, respectively, potentially having a great impact on the activity of this mutant protein 
(Figure 17). 
 
Hdac4-/- and related mouse models  
The Hdac4-/- mouse has a variety of significant phenotypes and was shown to have early 
onset chondrocyte hypertrophy and premature bone ossification [104].  These mice present with 
severe bone malformations and are much smaller than wild-type littermates due to premature 
ossification of the developing bone.  A reflection of the importance of HDAC4 in bone 
malformation in humans can be seen when studying the hands and feet of SMS117 and SMS272 
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(Figure 16).   In addition, in the same manuscript by Vega et al. 2004, it was shown that HDAC4 
also directly controls Runt-related transcription factor 2 (Runx2) activity.  The Hdac4-/- mouse 
model directly mimics the phenotype seen with constitutive Runx2 expression in chondrocytes 
[111, 112].   
MEF2C activity which is necessary for proper chondrocyte hypertrophy and bone 
development is also regulated by HDAC4 [113, 114].  Mice deleted for the Mef2c gene have 
impaired hypertrophy, cartilage angiogenesis, ossification, and longitudinal bone growth, a 
converse phenotype to that of the Hdac4-/- mouse [115], consistent with HDAC4 acting as a 
negative co-repressor of MEF2C.  
 
Clinical implications  
In the analysis of twenty 2q37 deletion cases, Aldred et al. concluded that the region most 
likely associated with congenital heart defects in the BDMR syndrome included the HDAC4 
gene.   In this report, we support this finding with the fact that SMS117 has a significant cardiac 
defect.  The role of HDAC4 in cardiac development is further supported by data that implicate 
MEF2C, which is regulated by HDAC4, in cardiac development [116].  Additional studies and 
cases are required to confirm this hypothesis. 
Based upon our findings reported here, we conclude that haploinsufficiency of the 
HDAC4 gene results in BDMR.  Data support a significant role for HDAC4 in normal skeletal 
development, specifically in metacarpal and metatarsal growth and craniofacial development, 
and in neuronal function, with a prominent role in behavior.  Autism or autism spectrum disorder 
(ASD) has been reported in many cases with 2q37.3 deletions, and with behavioral and 
developmental findings consistent with the cases we report here [107, 117, 118, 119].  However, 
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two of our older cases are reported to be "very friendly" but with poor communication skills, 
while the younger subjects have significant speech delay and poor communication with 
behavioral problems often prohibiting positive interactions.  These findings suggest that reduced 
expression or function of HDAC4 is a contributor to the ASD phenotype observed in many cases 
with 2q37 deletion but that interpersonal skills may improve with age and with reduction of 
negative behaviors.  Given that the genetic basis of autism is highly complex, it is not surprising 
that autistic behavior was also reported in case 2282 with a terminal 2q deletion that does not 
include HDAC4 and in a published case with a much smaller subtelomeric deletion suggesting 
that multiple genes at 2q37 may be involved in this phenotype [120].  A more proximal locus, 
CENTG2 at 2q37 (now renamed AGAP1), has also been suggested by two-point linkage analysis 
in autism families, although this was not supported by multipoint analysis [121]. 
Additionally, a recent publication by Klopocki et al. 2010 [122], has linked mutations in 
the parathyroid hormone related protein (PTHLH) to result in brachydactyly type E.  
Interestingly, Pthlh was identified as an inhibitor of Runx2 (regulated by Hdac4) in mice [123], 
and Pthlh-/- mice results in lethal short-limbed chondrodysplasia and speaks to the probability of 
common pathway involved in the development of metacarpals and metatarsals in the hands and 
feet in humans.      
Given the significant phenotypic overlap with Smith-Magenis syndrome, BDMR and 
SMS should be considered together in the differential diagnosis.  While type E brachydactyly is 
unique to BDMR, it is only penetrant in 50-60% of cases, so its absence does not remove the 
possibility of a positive diagnosis for BDMR.  Also, other phenotypes within the syndrome also 
show variable expressivity, especially heart defects and behavioral problems.  Given this 
variability, a genetic “two hit” model is the most likely applicable to neuropsychiatric disorder 
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[124] and given the range of phenotypes and variable expressivity seen dependent on deletion 
size this makes sense with regard to BDMR.  The diagnostic challenges and the elucidation of 
core phenotypes from syndrome to syndrome make it important to note all molecular findings 
and detail specific phenotypic findings in all cases.     
As such, we recommend molecular evaluation in cases with phenotypic findings 
consistent with BDMR and/or SMS for deletions involving chromosomes 2q37.3 and 17p11.2, 
respectively (karyotype, FISH, and/or aCGH).  For those cases without 2q37.3 deletion and with 
type E brachydactyly, sequencing of HDAC4 is appropriate.  For those subjects without a 
deletion of 17p11.2 and without type E brachydactyly, RAI1 sequence analysis should be 
undertaken, and if negative, followed by HDAC4 sequencing.  We anticipate additional 
mutations in the HDAC4 gene will be identified lending further support to this gene playing an 
essential role in proper cognitive, bone, and cardiac development in humans.  
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Chapter 5 
RAI1 transcriptionally regulates CLOCK and is a major contributor to 
circadian homeostasis 
 
Introduction 
 The retinoic acid induced one gene is the gene that when mutated or deleted results in 
Smith-Magenis syndrome.  However, little is known about the molecular function of RAI1.  
Given the phenotypic consequences of RAI1 mutation or deletion, RAI1 must be involved in 
pathways associated with development, behavior, neurological function, and circadian rhythm.   
Mutations in transcription factors have long been associated with human disease, 
including ATRX syndrome, myeloid leukemia and autoimmune dysfunction [125].  Because 
transcription factors can regulate many genes, deciphering their global function can be difficult.  
With concern to RAI1, there is an additional layer of complexity because, other than 
bioinformatic analysis, very little is known about the true molecular function of RAI1.   
Rai1, originally called Gt1,  was identified in  mouse P19 embryonal carcinoma cells 
which can be differentiated into neurons and glial cells when treated with retinoic acid [126], and 
three human isoforms are predicted by bioinformatic analysis.  RAI1 contains a plant 
homeodomain (PHD), and a bipartite nuclear localization signal, which are commonly seen in 
transcription factors (Figure 18).  PHD domains typically bind zinc and are involved in 
chromatin remodeling, whereas nuclear localization signals have the ability to recruit chaperone 
proteins, therefore facilitating transport into the nucleus [127].  Transcription factors will then 
either bind directly to nuclear DNA or other proteins which will form the initiation complex, to 
start of transcription via RNA polymerase II.  However, transcription factors can also repress 
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transcription acting to a negatively regulate transcription by blocking the enhancer binding 
regions. 
 Past studies have shown that Rai1 is expressed in all tested tissues and highly expressed 
in neural tissue [126].  We have previously shown that an RAI1 protein tagged with GFP (RAI1-
GFP) localizes to the nucleus (Figure 18) (Burnes et al. in review).  Complicating the story, the 
three predicted isoforms of RAI1 may serve different functions dependent on spatial and 
temporal expression. 
Identification of genes targeted by transcription factors can be difficult.  Before the 
advent of newer technologies, initial screens for gene targets of transcription factors could be a 
very labor intensive task [128].  Traditionally, the project would start with a chromatin 
immunoprecipitation using agarose beads bound to an antibody specific for the protein of 
interest.  The protein would be pulled down with chromatin bound to the protein of interest, in 
complex with the antibody coated beads, and these chromatin fragments would be cloned into 
plasmids.  Sequencing of these plasmids would follow.  Hundreds of these individual clones 
would have to be sequenced making this process very time consuming [128].  Recently, 
chromatin immunoprecipitation coupled with microarray has become an important tool in 
deciphering the targets of transcription factors.  Global ChIP-chip is a high throughput and 
effective tool for screening the regulatory regions of all known genes and has reduced the time 
needed to identify targets of transcription factors [129].  Through this set of studies we set out to 
identify genes regulated by RAI1. 
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Figure 18.  RAI1 localization and genomic and protein structure of RAI1.  A) HEK293 cells 
transfected with RAI1a-GFP.  B) The top panel shows genomic structure of RAI1 (isoform A) 
with 6 exons (4 coding: yellow and 2 noncoding: black). The bottom panel shows the protein 
structure of RAI1 including the polyglutamine (Poly-Q) and polyserine (Poly-S) tracts, the 
bipartite nuclear localization signals (NLS), and a C-terminal PHD (plant homeodomain). 
Created, in part, by Santhosh Girirajan.  
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Circadian rhythm 
Mammalian circadian rhythm is an essential regulator of not only the sleep-wake cycle 
but also body temperature, feeding cycles, hormone secretion, drug and xenobiotic metabolism, 
glucose homeostasis, and cell-cycle progression [130].  The master regulator of the circadian 
clock resides in the suprachiasmatic nucleus located in the mammalian hypothalamus.  The 
primary synchronizer of this clock is the 24 hour light dark cycle.  Over this 24 hour light dark 
cycle, a feed back loop of gene transcription and subsequent degradation of gene products occur 
signaling the mentioned processes to react accordingly.  Because of the complexity of this 
circadian loop, disturbances in the timing of gene expression can have a major impact on not 
only one’s sleep pattern, but also ones disease susceptibility and behavioral stability.  Genes 
involved in fatty acid metabolism, energy metabolism, and cholesterol biosynthesis seem to be 
expressed in a circadian manner  [130] so one can anticipate that sleep disturbance could be tied 
to obesity and increased risk for disease.  Interestingly, mice with a homozygous mutation in the 
gene Clock (one of the first and most important circadian genes identified) are obese and 
hyperphagic [131].  Further, altered circadian rhythm has been linked to bipolar disorder [132], 
and variants in CLOCK have been linked to sleep disorders in humans [133].  It has been shown 
through caregiver surveys that partial alleviation of the sleep disturbance in patients with SMS 
can result in behavioral improvement [134] 
 
Materials and methods 
Creation of Plasmids 
RAI1Flag:  RAI1 coding sequence was cloned into pEntr/D-TOPO using standard 
manufacturer protocols (Invitrogen, Carlsbad, CA).  A 5’ TOPO poly linker was added to cDNA 
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PCR forward primer (CACC) to ensure proper directional cloning.  Following PCR 2 uL of PCR 
product was mixed with 1uL salt solution, 2 uL ddH20, and 1 uL pEntr/D-TOPO.  The reaction 
was transformed into One Shot® Competent E. coli (Invitrogen, Carlsbad, CA) according to 
manufacturer’s instructions.  Cells were spread on LB plates containing 50 µg/ml kanamycin.  
After 18 hours colonies were picked and mixed with LB broth containing 50 ug/ml kanamycin 
and shaken for 18 hours at 370C.  Plasmid DNA was isolated using Fermentus GeneJETTM 
plasmid mini kit (Burlington, Ontario, Canada) according to standard manufacturer’s 
instructions.  Inserts were confirmed using RAI1 cDNA primers and sequenced using standard 
Sanger techniques.  Next, RAI1pEntr/D-TOPO was recombined with pDest26Flag  [135]using the 
standard gateway protocol provided by Invitrogen(Carlsbad, CA) to create pDest26RAI1Flag.    
CLOCKLuc:  The CLOCK 1st intron element was PCR amplified using standard 
techniques (forward primer:5’-GGACCTTTGCAAGAGCCCAAG-3’, reverse primer: 5’-
GCAGAGCACAGAGGGCTTTTAGGCCGATGT-3’) and cloned into StrataClone™ PCR 
Cloning vector using the standard protocol provide by the manufacture(Agilent Technologies, 
Santa Clara, CA) creating CLOCKStrata plasmid.  The insert was confirmed by standard Sanger 
sequencing, and removed by restriction digest with KpnI and SacI enzymes (New England 
Biolabs, Ipswich, MA).  The resulting product was run on a 2% agarose gel for 30 min and 
purified using Qiagen (Germantown, MD) Qiaquick gene extraction kit according to standard 
manufacturer’s protocols.  Kpn1 and Sac1 enzymes were then used to “prepare” the pGL3pro 
vector (Promega Corp, Madison, WI) and the cut out insert from CLOCKStrata was directionally 
ligated into the pGL3pro vector to create CLOCKLuc using standard T4 ligation protocols 
provided by the manufacturer (Promega Corp, Madison, WI).   
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Transfections 
Human embryonic kidney (HEK293T) cells were maintained in 6-well dishes containing 
Dulbecco's modified Eagle's medium with 10% (v/v) FBS, 2 mM L-glutamine, and 100 µg/ml of 
penicillin/streptomycin (Invitrogen, Carlsbad, CA) at 37°C in a 5% CO2 incubator. The cells 
were counted using trypan blue exclusion to ensure >90% viability. Transfections with pUC19, 
psvβ-Gal, BDNFLuc and RAI1Flag were performed by lipofection using LipofectamineTM 2000 
(Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Briefly, ~4 x 105 cells 
were plated in 2.0 ml of growth medium without antibiotics 24 hours prior to transfection.  A 
total of 4 ug of total plasmid DNA, using pUC19 plasmid as “filler” DNA,  was diluted in 250 ul 
OptiMEM® Reduced Serum Medium (Invitrogen, Carlsbad, CA). Similarly, 10 ul of 
LipofectamineTM 2000 was diluted in 250 µl of OptiMEM® Reduced Serum Medium, mixed 
well, and incubated for 5 minutes. After incubation, diluted plasmid DNA was mixed with 
diluted LipofectamineTM 2000 to a total volume of 500 µl and incubated for 20 minutes. 
Plasmid:Lipofectamine complexes (500 µl)  were added to each well and mixed by rocking. The 
cells were then incubated at 37°C in a 5% CO2 incubator, for 24 hours before Trizol RNA 
extraction using standard protocols provided by Invitrogen (Carlsbad, CA).  
 
Luciferase assay 
Twenty-four hours after DNA transfections cells were washed with 2 mL DPBS 
(Invitrogen, Carlsbad, CA), and Tropix Glacto-LightTM (Applied Biosystems, Bedford, MA) 
standard protocol was used.  Briefly, 250 uL of lysis solution was added to each well of the six 
well plate and scraped until all cells were detached.  Lysates were collected and centrifuged at 
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12,000 RPM for 2 min to pellet cell debris. Next, of the resulting supernatant 50 uL was 
transferred to a 4 wells of a 96 well white luminometer plate.  Two wells were treaded with 70 
uL diluted Galacton® substrate (1:100, Galacton:Reaction buffer diluent) and incubated for 30 
min.  To the 2 wells that contained the diluted Galacton® substrate, 100 uL of Accelerator(-II) 
was added.  To the 2 wells that did not contain the diluted Galacton® substrate, 100 uL of 
Steady-Glo® Luciferase substrate (Promega Corp, Madison, WI) was added.  Each well was 
read using the Wallac 1420 VICTOR2™ luminometer (PerkinElmer, Waltham, MA) on a 
maximum linear scale.      
 
Calculation of relative luciferase activity 
Relative luciferase activity, from each individual transfection, was calculated by dividing 
the average number of light units read from the wells containing the Steady-Glo® Luciferase 
substrate (Promega Corp, Madison, WI) by the average number of light units from the wells 
containing the Galacton® substrate and Accelerator(-II).  The equation (∆Luc/∆β-Gal=Relative 
luciferase activity) was used.  Wells containing pUC19, psvβ-Gal, and CLOCKLuc was used as 
baseline luciferase activity.  Each experiment was performed independently no less than three 
times.   
 
Statistical analysis 
P-values were generated by averaging relative luciferase activity from each independent 
study and performing a two-tailed student’s t-test.  Standard deviations were generated using 
Excel.     
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Mouse tissue collection 
Rai1+/- mice were obtained from the Jackson labs [42]. These mice were bred with wild-
type C57Bl/6J females to obtain Rai1+/- and wild type pups. Genotyping was performed using 
PCR primers, reported in Bi et al 2005, specific for the Rai1-targeted allele and the wild type 
allele [42].  Mice euthanized in the day time hours were taken at ~8 hours Zeitgeber time and 
mice euthanized in the night time hours were taken at ~16 hours Zeitgeber time.  WT C57Bl/6J 
and Rai1+/- mice were euthanized by CO2 anesthesia and tissues were collected in accordance 
with standard protocols and frozen at -80oC.   
 
Quantitative PCR 
qPCR was performed as previously described [81].  
 
Chromatin immunoprecipitation with microarray (ChIP-Chip) 
HEK293t cells were transfected with RAI1Flag plasmid as stated above by scaling the 
reaction up for a T75 culture dish.  ChIP-Chip was processed with mouse IgG Dynabeads 
(Invitrogen, Carlsbad, CA) and monoclonal anti-Flag IgG antibody produced in mouse (Sigma 
Aldrich, St. Lewis, MO) according to manufacture’s protocols using Nimblegen “ChIP sample 
preparation protocol v2” (Roche Nimblegen, Madison, WI).  Briefly, after 24 hours, transfected 
cells were formaldehyde treated to cross-link protein complexes with nuclear chromatin and 
frozen at -80oC overnight.  Nuclei were next isolated by cytoplasmic lysis and centrifugation.  
Isolated nuclei were then sonicated on ice with a Branson Sonifier, used at 25% power, to shear 
DNA:protein complexes to between ~200 and 800bp.  Lysates were then centrifuged at 4,000 
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RPM at 4oC to pellet debris.  Protein:chromatin products were then mixed with IgG Dynabeads, 
that had been washed and mixed with anti-Flag IgG antibody at 4oC for 24 hours, for 16 hours 
overnight.  Using a DynaMag™-Spin magnet (Invitrogen, Carlsbad, CA) protein:chromatin 
products were isolated and nuclear extracts discarded.  Chromatin;protein complexes were then 
washed 6 times according to manufacturers protocols and the crosslink was reversed by using 
heat treatment at 65oC for 16 hours.  Following reverse crosslink chromatin products were whole 
genome amplified, as per recommendation by Nimblegen, by using WGA2-10RXN kit (Sigma-
Aldrich, St. Lewis, MO).  
Arrays were processed by Nimblegen using the Nimblegen HG18 RefSeq promoter array 
according to standard manufacturer’s protocols.  Control chromatin was processed as per 
manufacturers instructions using nuclear DNA isolated from HEK293t cells that were non-
transfected and non-cross linked but were sonicated as stated above.  Data were pre processed by 
Nimblegen according to standard manufacturer’s protocols.  RAI1Flag binding sites were 
generated by using genomic data points, Peak_Start and Peak_End, from Nimblegen pre-
processed data files.   
 
Candidate gene filtration 
Ideally, regions of potential RAI1 binding would replicate between both ChIP-Chip 
experiments but this was not a defined criteria.  RAI1 probable “hits” were defined by false 
discovery rate (FDR<.20), preprocessed by Nimblegen, reproducibility between arrays, known 
biological function, and Signal Map peak score (Roche Nimblegen, Madison, WI).  FDR “is 
generated from the scaled log2-ratio data. NimbleScan detects peaks by searching for 4 or more 
probes whose signals are above the specified cutoff values, ranging from 90% to 15%, using a 
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500bp sliding window. The cutoff values are a percentage of a hypothetical maximum, which is 
the mean + 6[standard deviation]. The ratio data is then randomized 20 times to evaluate the 
probability of “false positives.” Each peak is then assigned a FDR score based on the 
randomization (Roche Nimblegen, Madison, WI).” Peak scores were identified by loading 
preprocessed .GFF files.  Peak scores are between 1-4 and only scores between 1-2 were 
considered.  Peak scores are based off of an algorithm created by Nimblegen.  
 
Results 
Chromatin immunoprecipitation with microarray 
Genes identified by ChIP-Chip: 
Two independent ChIP-Chips were performed by transfecting RAI1Flag plasmid into 
HEK293 cells.  HEK293 cells were used because of their ease of transfection and biological 
relevance as RAI1 is highly expressed in the human kidney [136].  
By performing the two ChIP-chip experiments in HEK293 cells we were able to identify 
257 transcripts which overlap between the arrays (Figure 19, Table 12 ).  As suspected, we 
identified genes important in circadian rhythm, cognition, chromatin modification, development, 
and neurological stability were identified  (Figure 19, Table 12).  To refine our candidate gene 
list which would be further explored we used SignalMap software (provided by Roche 
Nimblegen), and known biological function to pick the best transcripts of interest.  Peak scores 
range from 1-4. Peaks created in SignalMap which held a value of 1 or 2 were identified as best 
hits.  A value of 1 or 2 correlates with a low false discovery rate and high log2 ratio of 
test/control indicating a high scoring peak.  A ranked order of top genes can be seen in Table 13.  
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Table 12.  List of gene regulatory regions which overlap between RAI1 ChIP-Chip arrays.   
ABCB1 CHODL HIST1H2AC LOC642891 OR52A1 POU1F1 TNFSF5IP1 
AGL CHRNA5 HIST1H2BL LOC646215 OR52N5 PRKACB TRPC3 
AKAP7 CLEC5A HIST1H2BM LOC81558 OR56B1 RAP1B TRPM8 
AKR1C1 CNTF HIST1H3H LPHN2 OR5B2 RGS21 TUSC1 
AKR1C3 COG6 HIST1H4B LRRN3 OR5BU1 RHOB TXNDC13 
ALS2CR16 COMMD3 HIST1H4J LRRTM4 OR5H14 RP1-32F7.2 UBE3A 
AMELY CRBN HLA-DPA1 LST-3TM12 OR5H6 RP11-35N6.1 UFM1 
AMY2B CREM HLA-DPB1 LUM OR5K3 RP11-54H7.1 UGT2A1 
ANXA1 CRYGS HS322B1A MAS1L OR5K4 RP13-11B7.1 UNQ9356 
APIN CYLC2 HSFY1 MEF2A OR5M3 RREB1 UTS2D 
APRT CYorf15A HSFY2 MEP1A OR5R1 RSRC1 UTY 
ARHGEF7 CYorf15B HSN2 MGAT4C OR5T2 SERPINI2 VWA2 
ASAH2 DEFB112 HTR2B MGC33530 OR5V1 SGCG WDSOF1 
ASB4 DGKB IFNA10 MGC34713 OR5W2 SGCZ XRN1 
ATF6 DIAPH3 IL12RB2 MGC35043 OR6M1 SHOX2 YIPF7 
ATP5E DNAJC5B IL15 MGC35212 OR8H1 SI ZNF306 
AZI2 DSPP IL17D MKRN3 OR8H2 SLC12A1 ZNF614 
BAZ2B DTNA IMPG2 MMP13 OR8I2 SLC16A7  
BCHE ELOVL2 INVS MTRF1L OR8K3 SLC25A32  
BMP5 EYA1 JMJD1A MUC7 OR9G1 SLC26A7  
C10orf61 FAM55D KCNK10 MYL1 OR9G9 SLCO1B3  
C10orf68 FBXL7 KCNMB4 N/A OTUD6B SLITRK6  
C14orf10 FBXO4 KCTD4 NAP1L3 PALLD SMC6L1  
C14orf150 FGB KIAA0391 OGN PCDH11X SNPH  
C20orf103 FGF7 KIAA1712 OMD PCDH15 SNRPN  
C21orf34 FGL2 KLF14 OR10T2 PCDHA1 SPAG6  
C3orf58 FH KLHL4 OR11H4 PCDHA11 SPANXA1  
C4BPB FLJ22662 KLHL9 OR13C3 PCDHA3 SPANXA2  
C4orf7 FLJ32745 KLRC4 OR13F1 PCDHB16 SPANXE  
C9orf102 FLJ43706 KLRK1 OR1Q1 PCDHB8 SPATA18  
C9orf150 FLJ44048 KRT12 OR2B11 PCDHGA12 TAF2  
CAB39L FLJ46120 KRT24 OR2J3 PCDHGA9 TAIP-2  
CCDC46 FOXK2 KRTAP1-1 OR2L2 PDE1A TAS2R7  
CD69 FYTTD1 KRTAP1-3 OR2L3 PHIP TAS2R8  
CDH12 GABRG1 KRTAP4-12 OR2M5 PHYHIPL TDRD4  
CDY2B GALNT13 KRTAP6-3 OR2T10 PIGF TEX15  
CENTD1 GLRA3 LCE3B OR2T4 PLCB4 TFEC  
CEP76 GPR52 LEF1 OR4A47 PLRG1 TMEM77  
CEPT1 HHLA2 LOC129285 OR4C16 PMCH TMPRSS11B  
CHL1  LOC401137 OR51A7 PNLIP TNFSF18  
Full gene names are provided in Appendix E.   
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Figure 19.  ChIP-Chip arrays.  A) 
Total number of genes identified in n=2 
independent ChIP-Chip experiments.  
Overlapping genes identified for further 
evaluation = 257.  B) Pathways 
identified using Panther analysis 
(http://www.pantherdb.org/).   
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Table 13.  Ranked order of top 10 gene regulatory regions identified in ChIP-Chip experiments.  Disease relevance collected 
from Panther (www.pantherdb.org) and PubMed (http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed) 
Gene Symbol Gene Name Disease Relevance FDR 
SNRPN Small nuclear ribonucleoprotein polypeptide Prader-Willi and Angelman syndromes 0.05 
UBE3A Ubiquitin protein ligase E3A Angelman syndrome 0.10 
BDNF Brain-derived neurotrophic factor Obesity, neurotransmission, metabolism 0.18 
CLOCK Circadian locomotor output cycles kaput  Sleep, circadian rhythm mood disorder, schizophrenia, insomnia, obesity 0.19 
MEF2A Myocyte enhancer factor 2A 
Muscle development, neuronal differentiation, cell growth control, 
apoptosis 0.15 
BMP5 Bone morphogenetic protein 5 Skeletal development, dendritic growth 0.01 
TRPC3 
Transient receptor potential cation channel, 
subfamily C, member 3 Alzheimer syndrome, BDNF function 0.14 
BCHE Butyrylcholinesterase 
Neurotransmission, drug metabolism, skeletal muscle development, 
butyrylcholinesterase deficiency 0.15 
CREM cAMP responsive element modulator Apoptosis, transcription, cell cycle regulation  0.09 
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Genes identified for further evaluation  
CLOCK:  The mammalian circadian locomotor output cycles kaput (CLOCK) was identified and 
cloned by King et al. [137] in 1997. CLOCK is thought to be the master regulator of the central 
clock of circadian rhythm.  The protein product of the CLOCK gene is a basic-helix-loop-helix 
transcription factor and heterodimerizes with BMAL1 to activate transcription of a variety of 
downstream genes essential for proper modulation of circadian rhythm.  The period genes 
(PER1, PER2, PER3), the cryptochrome genes (CRY1, CRY2), the nuclear receptor subfamily 1 
group D member 2 (NR1D2/Rev-Erbβ), and RAR-related orphan receptor A genes (RORA, 
RORB, RORC).  All of these genes have an E-box (consensus sequence: CANNTG) to which the 
CLOCK/BMAL1 complex binds.   
SNRPN: The small nuclear ribonucleoprotein polypeptide N (SNRPN) resides in the Prader-
Willi/Angelman syndromes region on chromosome 15q11.2.  The protein encoded by this gene 
is one polypeptide of a small nuclear ribonucleoprotein complex and belongs to the snRNP 
SMB/SMN family. The protein may play a role in pre-mRNA processing.  Although individual 
snRNPs are believed to recognize specific nucleic acid sequences through RNA-RNA base 
pairing, the specific role of SNRPN is unknown. The genomic location of SNRPN is on the 
opposite strand of the SNURF gene (SNRPN upstream reading frame) being transcribed on the 
sense strand.  The 5' UTR of SNRPN has been identified as an imprinting center.  The most 
common cause for Prader-Willi syndrome (PWS) is paternal microdeletion of SNRPN 
(del(15)(q11-q13)pat) resulting in ~70% of cases, while the second most common cause is 
maternal uniparental disomy (UPD) of chromosome 15 (15 (upd(15)mat)) [138].  Interestingly, 
there is strong overlap between the physical and behavioral phenotypes seen in PWS and SMS.  
This gene is being pursued by Anam Bashir (Elsea Lab)      
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UBE3A: Ubiquitin protein ligase E3A (UBE3A) is located on chromosome 15q11.2 and 
functions to target proteins for degradation.  Ubiquitination is an important step in all cells as 
dysfunctional gene products must be removed from the cellular machinery by cellular structures 
such as proteasomes.  UBE3A is ubiquitously expressed from both the paternal and maternal 
alleles except for the brain where only the maternal copy of the gene is expressed and the 
paternal copy is imprinted.  Maternal deletion, mutation, or imprinting error of UBE3A results in 
Angelman syndrome (AS).  The most common lesions leading to AS are a common large 
deletion of 15q11-q13 (~70%), paternal uniparental disomy (~1%), and an imprinting defect 
(~4%) [138].  Additionally, UBE3A mutation account for approximately 8% of cases [139]. 
Paternal UPD led investigators to the conclusion that AS involves a maternally expressed gene. 
Based on the finding of point mutations in patients with AS, UBE3A has been identified as the 
gene affected in AS.  Interestingly, imprinted UBE3A expression is restricted to the brain only.  
 
BDNF:  Brain-derived neurotrophic factor (BDNF) is located on chromosome 11.  It is 
primarily active in the hippocampus, cortex, basal forebrain, cerebellum and olfactory bulb.  It is 
also found in the retina, central nervous system (CNS), motor neurons, kidneys, and the prostate.  
BDNF functions in neuronal survival, growth and differentiation of new neurons and synapses, 
as well as  control of food intake.  BDNF has recently been reported to regulate food intake and 
glucose homeostasis in genetically obese animal models [140].  The Bdnf+/- mouse exhibits 
hyperphagic behavior and dramatic obesity [141].  Haploinsufficiency for Bdnf in mice was 
found to cause increased food intake, early-onset obesity, hyperactivity, and cognitive 
impairment [141].  Previous studies have also shown that up regulation of Bdnf rescued synaptic 
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plasticity, long-term memory deficits and behaviors of the mutant Huntington’s disease mice 
[142].  In vitro overexpression of Bdnf increased axonal length and axonal branching in Rett 
syndrome, while preventing the decrease in dendritic length commonly seen with the disease 
[143].  This gene is being pursued by Sun Kim (Elsea lab)   
 
RAI1 transcriptionally activates CLOCK via an intron 1 enhancer element 
The downstream targets of CLOCK are well characterized.  However, the transcriptional 
regulator of CLOCK has not been defined.  Using peak data acquired from our duel ChIP-Chip 
assays we were able to identify a ~350 bp region where RAI1Flag possibly binds.  This element 
resides in intron 1 (Chr4:56072089- 56072440).  Primers designed to flank this region were used 
to amplify this piece of genomic DNA, which was first cloned into the StrataClone TA cloning 
vector and then was subcloned into the pGL3-Promoter vector (CLOCKLuc) which contains an 
SV40 promoter that provides baseline luciferase activity. 
When RAI1Flag is transfected with CLOCKLuc there is a greater than 2-fold increase in 
luciferase activity (Figure 19).  Taken together, the ChIP-Chip and luciferase data suggest that 
RAI1 binds, directly or in a complex, to the 1st intron of CLOCK, enhancing its transcriptional 
activity in vitro.  Given these findings, it was logical to move forward with in vivo studies 
utilizing the Rai1+/- mice.    
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Figure 20.  RAI1 impact on CLOCK transcription.  A) Intron 1 CLOCK enhancer region used for luciferase assays.  Shown in red: 
~350bp region identified in Nimblegen array as most likely binding region of RAI1Flag.  Shown in yellow: Proposed RAI1 consensus 
binding sites as reported by Eri Kamura (Elsea Lab).  Shown in black:  PCR primers used to clone region (CLOCKLuc) used for 
luciferase assays (724 bp).  B) Luciferase activity of co-transfection of RAI1Flag with CLOCKLuc plasmids. N=3 studies with readings 
taken in duplicate.  *, P=0.009.   
A 
B 
* 
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Dysregulation of circadian genes in Rai1+/- mice  
 Rai1+/- mice are obese, hyperphagic, have decreased sensitivity to pain, low muscle 
strength, and an altered circadian rhythm [42, 45, 144].  Expression analysis of Rai1+/- kidney 
and whole brain shows a marked decrease in both Rai1 and Clock (mouse orthologue to CLOCK) 
(Figure 20).  Additionally, expression of Rai1 and Clock in the mouse hypothalamus showed 
reduced expression (Figure 21 ).  Further, we analyzed the expression of downstream targets of 
Clock including Per2, Npas2, and Nr1d2 in the mouse hypothalamus, all of which had reduced 
expression as compared to WT C57Bl/6J littermates during the day time hours.  These data show 
that there is circadian dysregulation of gene expression in the Rai1+/- mouse hypothalamus. 
Next it was important to measure circadian gene expression in the mouse hypothalamus 
during the day time and night time hours to ensure that rhythmicity was not restored with regard 
to external cues such as feeding.  Our results show that during the dark phase the expression of 
core circadian genes is dysregulated including Per2 which when knocked out in mice results in a 
severe circadian phenotype [145] and Nr1d2 which was identified as one of the top genes with 
reduced expression in a study of human cells knocked down for RAI1 [81] (Figure 22).  
Interestingly, Clock expression is upregulated in night time, suggesting a malfunction of the 
autoregulatory feedback loop.  
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Figure 21.  Rai1 and Clock expression in mouse tissues.  A-B) Mouse Brain.  C-D) Mouse Kidney.  N=3 mice per tissue.  All mice 
sacrificed during the day time hours.  
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Figure 22.  qPCR of circadian genes expressed in mouse hypothalamus.  N=3 mice per tissue.  All mice sacrificed during light 
phase.   
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Dysregulation of circadian genes in SMS fibroblasts 
 Human fibroblasts follow a 2 4hr rhythmicity in vitro just as they would in vivo.  To 
assess the circadian cycling of RAI1, CLOCK, and NR1D2 we took RNA samples from 
unaffected (GM637), deletion (SMS182), and mutation (SMS175) cell lines.   Transcription of 
all of these genes is dysregulated when compared to unaffected fibroblasts.  It is worth while to 
note that the hypothesis to date, with regard to the inverted circadian rhythm seen in SMS, is that 
an inverted secretion of melatonin causes sleep disturbance.  The data presented here suggest that 
this inverted circadian rhythm is likely due to a dysregulation of circadian gene expression, and 
the inverted melatonin secretion seen in the majority of cases is likely a byproduct of said 
dysregulation.  Further supporting our hypothesis is the fact that C57BL6 mice do not secrete 
melatonin [146].  
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Figure 23.  qPCR of core circadian gene expression in the mouse hypothalamus during day 
light (white boxes) and night time (black boxes) periods.  Circadian rhythm remains disrupted 
during both light and dark phase hours relative to WT baseline at the same phase (1, dotted line).  
N=3 mice per tissue.    
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Figure24.  Core circadian gene expression in unaffected and SMS fibroblasts.  N=3 qPCR experiments per cell line performed in 
triplicate.  
BAB239 = RAI1 deletion 
SMS175 = RAI1 mutation 
SMS182 = RAI1 deletion  
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Discussion 
 The circadian rhythm defect seen in Smith-Magenis syndrome is thought to contribute to 
a more severe behavioral phenotype  [14].  It is thought that if sleep rhythmicity is resolved, 
treatment of behavior becomes easier.  This is why it is imperative to understand the molecular 
defects that result from RAI1 mutation or deletion.  
RAI1 is a proposed transcription factor containing a PHD domain and nuclear 
localization signal.  However, it was previously unknown in what biochemical pathways RAI1 
functions and what genes it may regulate.  Identification of the molecular changes and 
subsequent affected pathways that result from RAI1 haploinsufficiency holds the potential for 
chemical, habitual, or nutritional based interventions.    
 The Clock/Clock mutant mice were created my King et al. in 1996 [147].  By using a 
forward genetics approach, mutagenesis followed breeding and positional cloning, the authors 
identified a mutant mouse with an A to T splice site mutation which results in deletion of 51 
amino acids of the protein.  This mutation disrupts exons 16, 17, and 18 of the 24-exon gene 
product. This Clock mutant mouse was bred to generate the Clock/Clock mutant mouse which 
has an erratic and unpredictable circadian sleep cycle, with loss of periodicity, as compared to 
WT littermates indicating its importance in circadian homeostasis [137].  As a complementary 
approach to positional cloning, Antoch et al. 1997 [148] used in vivo complementation with BAC 
clones expressed in transgenic mice to identify the circadian Clock gene. A Clock transgene 
completely rescued both the long-period and the loss-of-rhythm phenotypes in Clock mutant 
mice.  These over expressing Clock mice revealed a shortened period length lending to the fact 
that Clock is a dosage sensitive gene.  Surprisingly, when DeBruyne et al. created the Clock-/- 
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complete knockout there was no loss of rhythmicity, indicating that multiple genes may play a 
critical role as “master regulators” or have compensatory effects  [149].   
 As it is important to not only study the influence RAI1 has on CLOCK it is also necessary 
to analyze further downstream effects.  The period circadian protein homolog 2 (PER2) is a very 
important circadian transcript involved with the correct rhythmicity of circadian cycling.  The 
Per2 homozygous mutation mouse (Per2m/m) was created by Zheng et al. in 1999 [150].   This 
mouse contains a deletion in the PAS domain of the mouse Per2 gene.  The PAS domain is 
highly conserved in circadian clock genes from a variety of species [150].  The Per2m/m mouse 
exhibits a variety of circadian phenotypes including a shorter circadian period in normal 12 hour 
light/12 hour dark conditions, followed by loss of circadian rhythmicity in constant darkness as 
measured by wheel running measurements [150].  Additionally, Per1 mRNA levels were 
reduced in Per2m/m mice, indicating that Per2 is upstream of Per1 [150].  
 Further, Girirajan et al. 2009 [81] identified NR1D2 in a RAI1 knockdown study in 
HEK293t cells.  This study included siRNA knock-down of RAI1 followed by microarray 
analysis.  NR1D2 was one of the top genes down regulated in this study and adds to the validity 
of our findings.   
Polymorphisms in the key players of circadian rhythm (CLOCK, BMAL1, PER3) have 
been implicated in a variety of mood disorders in humans [151, 152].  Additionally, single 
nucleotide polymorphisms (SNPs) in CLOCK have been associated with defects including, 
bipolar disorder [153], insomnia with bipolar disorder [154, 155], major depressive disorder 
[156] and obesity.  Additionally BMAl1 [157, 158], PER3 [157] and TIMLESS [158] have all 
been associated with bipolar disorder. The behavioral phenotype seen in Smith-Magenis 
syndrome has also been described as manic in some cases lending to the idea that disruption of 
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the circadian rhythm may not only complicate the behavioral phenotype but contribute directly to 
it.    
Given the important role that CLOCK plays in circadian rhythm and its association with 
human disease, many studies have been performed to identify the function of CLOCK, but its 
transcriptional regulator(s) has remained vague.  Here we present data that suggest that RAI1 is 
an important enhancer of CLOCK transcription.  Using both in vivo and in vitro tools we were 
able to show that RAI1 regulates CLOCK via an enhancer region located in intron 1 which 
contains two proposed RAI1 consensus binding sites identified by Eri Kamura (Elsea lab) [159].    
These data suggest that RAI1 plays an important role in maintaining circadian rhythmicity 
and because circadian rhythms impact development, sleep, and behavior these findings should 
help to further delineate the pathways involved in syndromes wherein these functions are 
disrupted.  Additionally, as better treatments are developed to target these pathways, we may one 
day be able to correct many of the sleep and behavioral phenotypes seen in Smith-Magenis 
syndrome.  
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Chapter 6 
Summary 
These studies have identified new loci associated with a Smith-Magenis-like phenotype.  
We have shown that SMS and SMS-like cohorts are not different with regard to the core 
phenotypes seen most commonly in SMS.  We have also shown that alternate loci, that when 
deleted or duplicated, can result in a phenotype similar to SMS.  Additionally, we have been able 
to make phenotypic connections between SMS and SMS-like syndromes which has already 
improved diagnosis of these disorders (Chapter 2).   
 The broad aCGH study allowed us to explore in detail the deletion 2q23 syndrome.  
Using overlapping deletions from our case, as well as new and reported cases, we were able to 
better define the phenotype of this syndrome, as well as narrow the critical region to one gene, 
MBD5.  We believe that haploinsufficiency of MBD5 contributes to the major phenotypes in 
deletion 2q23 syndrome, including microcephaly, intellectual disabilities, severe speech 
impairment, and seizures (Chapter 3).  We believe that mutation screening of MBD5 in 
individuals with a similar phenotype is an appropriate next step in confirming the weight of 
contribution that MBD5 holds in this rare syndrome.   
 Additionally, using a similar approach as in Chapter 3 we were able to refine the critical 
region for Brachydactyly Mental Retardation syndrome (deletion 2q37 syndrome) and identified 
an insertion mutation of HDAC4 in one case, SMS117.  Mutation of HDAC4  likely contributes 
to the major phenotypes seen in BDMR and identification of more mutation cases is likely in the 
future (Chapter 4).  
 Lastly, we were able to characterize, in part, the molecular function of RAI1, the gene 
that when mutated or deleted results in Smith-Magenis syndrome.  There is a strong circadian 
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phenotype associated with SMS wherein subjects have consistent night awakenings with 
frequent day time napping.  We believe that RAI1 plays a significant role in the central circadian 
pathway.  Using both in vivo and in vitro methods, we have shown that RAI1 regulates CLOCK 
gene expression, which is a novel breakthrough, as the transcriptional regulators of CLOCK  
have not been defined (Chapter 5).   
 Taken together these studies have further defined and refined the molecular root  for each 
syndrome.  However, the question remains: “What specific pathways and genes are logical to 
explore in the future with regard to these syndromes and the impact of RAI1 on human 
development and behavior?” 
 
Development 
 In an exploratory bioinformatic study by Danielle Bartholomew (Elsea lab) MEF binding 
sites in the 5’ untranslated region of RAI1 were identified.  As stated above MEF2C activity is 
necessary for proper chondrocyte hypertrophy and bone development.  MEF2C is also inhibited 
by HDAC4.  Additionally, the bone morphogenic protein 5 gene (BMP5), a member of the 
transforming growth factor-beta superfamily of regulatory molecules, was identified in our ChIP-
Chip studies lending to the idea that RAI1 regulates it on the transcriptional level.  BMP5 is 
necessary for proper skeletogenesis, and BMP5 mutant mice have a variety of skeletal and soft 
tissue abnormalities [160].   It is also worthwhile to note that BMP5 has been shown to elicit 
dendritic growth in vitro [161], which may contribute to some of the neurological phenotypes 
seen in SMS.  In these studies we have shown that mutation of HDAC4 results in many of the 
features seen in SMS as well as distinct brachydactyly not seen in SMS, which is logical 
considering HDAC4 may be upstream of RAI1 (Figure 24).  My belief is that MEF2C is a 
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positive regulator of RAI1 transcription which is modulated by HDAC4.  I also believe that RAI1 
may be a positive regulator of BMP5 ultimately leading to proper skeletal development (Figure 
24).  However, it must be mentioned that HDAC4 is also a regulator of RUNX2 which is known 
to be necessary for proper skeletogenesis suggesting multiple pathways involved.  Additionally, 
as shown in Tables 12 and 13 RAI1 may regulate MEF2A suggesting a possible autoregulatory 
feedback loop with regard to RAI1 function in skeletogenesis.   
 
Behavior and sleep 
 The behavioral phenotypes seen in SMS and SMS-like syndromes are significant.  They 
include, but are not limited to, verbal outbursts, temper tantrums, self-abusive behavior, and 
stereotypies.  These phenotypes all have a strong neurological element and are complicated by 
sleep disturbance.  It has been shown that solving the sleep problems seen in SMS may relieve 
many of the behavioral phenotypes [14].  It is my proposition that RAI1 plays a major role in 
circadian rhythm and that when RAI1 is mutated or deleted the resulting behavioral phenotypes 
are a direct result of this haploinsufficiency. 
 We have shown here that RAI1 is a positive regulator of CLOCK, the master regulator of 
central circadian gene expression.  We used both animal models and cell based studies to show 
the disruption of the circadian cycle in SMS subjects.  CLOCK has been shown to be associated 
with a variety of disorders including schizophrenia, bipolar disorder, mania and depression all of 
which have elements seen in the SMS phenotype.  A schematic of the influence RAI1 has on the 
circadian cycle can been in seen in Figure 25.   
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Figure 25.  Proposed schematic of RAI1 contribution to proper skeletal development.  
HDAC4 negatively regulates MEF2C on the protein level which then leads to reduced RAI1 
transcription leading to skeletal, neurological and behavioral phenotypes .  Reduced RAI1 
transcription then leads to reduced BMP5 and MEF2A transcription which may then lead to 
neurological and skeletal phenotypes as well as malfunction of the proposed feedback loop.    
 
RAI1 
BMP5 
MEF2C/A 
MEF2A 
HDAC4 
 118 
 Theoretically, if CLOCK expression is reduced, downstream gene expression would also 
be reduced.  This could have a variety of impacts; molecularly, this reduction of CLOCK and 
downstream genes would also result in dysregulation of the regulatory feedback loops.  
Clinically, this could result in an altered sleep cycle, mood disorder and even learning disability 
and developmental problems.   
 
Future directions 
With regard to the SMS-like study and resulting studies (Chapters 2-4), I would like to 
see more subjects ascertained and screened for HDAC4 and MBD5 mutations.  I would also like 
to see molecular characterization of these mutations.  For example, cDNA from subjects with 
mutations could be collected and cloned into a variety of vectors.  A Flag vector already in use in 
the Elsea lab could be used to perform IP studies to identify presence or absence of specific 
binding partners.  Also, stable transfection of these mutant alleles could help to identify weather 
they are functionally active and able to perform their transcriptional roles on downstream genes.  
The molecular follow up will allow further insight into the pathways involved in these 
syndromes and how mutation specifically affects pathways.  I would also like to see a detailed 
panel of molecular tests, including aCGH, MLPA and gene sequencing, and phenotypic check 
lists developed such that the proper diagnosis for these individuals may be more easily acquired 
in the future, helping families, clinicians, and the subjects themselves.  
With regard to the molecular function of RAI1, I would like to see a variety of studies 
performed.  First and foremost I think that follow up with the remaining genes of interest from 
the ChIP-Chip study is imperative, specifically the top 10 genes identified in Table 13.  
Additionally, I would like to see a study performed that identifies binding partners of RAI1.  
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This can be easily performed utilizing the RAI1Flag plasmid already available with IP and mass 
spec analysis.  Alternatively, the RAI1 coding sequence could easily be cloned into a vector 
containing a HIS-tag and column chromatography could be utilized which may reduce some of 
the background associated with IP.  If RAI1 binds to a well characterized protein, this will allow 
us further insight into the molecular functions of RAI1 and possibly lead us to proteins that 
regulate RAI1 on the transcriptional level.  Cloning of the RAI1 promoter would also help with 
this endeavor (being pursued by Dr. Deborah Zies).   I would also like to see the Rai1+/- mice 
crossed with the Clock-/- mice which do not have a circadian phenotype.  If the resulting mice do 
have a strong circadian phenotype we may be able to identify alternative circadian pathways that 
RAI1 influences outside of CLOCK transcription.  These studies will not only help SMS and 
SMS-like subjects but could have impact on the general public and those with psychiatric 
disorders.   
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Figure 26.  RAI1 regulates clock transcription and is a major element in the circadian 
cycle.  Modified from Nolan et al. 2008. 
 
 
 
 
 
 
 
 
 
 
RAI1 
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Overexpression of RAI1 in HEK293t cells 
 As stated in Chapter 1, duplication of 17p11.2 results in dup17p11.2 syndrome (aka 
Potocki-Lupski syndrome).  This syndrome is rarer than SMS, but because duplication of this 
genomic region, including RAI1, gives rise to a recognizable syndrome, it points to the fact that 
RAI1 is a dosage-sensitive gene.  Additionally, Girirajan et al. 2008, 2009  [43,[44] showed that 
Rai1-Tg mice have altered maternal behavior, altered sociability, and impaired serotonin 
metabolism  [44].  Further, these mice have growth retardation, increased locomotor activity, and 
abnormal anxiety-related responses.  Rai1-Tg mice also have an altered gait with short strides 
and long sways, impaired ability on a cage top hang test, decreased forelimb grip strength, and a 
dominant social behavior.  Additional analyses of homozygous transgenic mice revealed a 
dosage-dependent exacerbation of the phenotype, including extreme growth retardation, severe 
neurological deficits, and increased hyperactivity [43].   
 These results laid the groundwork to examine the molecular changes that occur because 
of RAI1 overexpression.  We used transient over expression followed by gene expression 
microarray to explore the consequence of RAI1 overexpression.   
 
Materials and methods 
Transfections 
 Transfections of HEK293t cells with RAI1Flag were performed as described Chapter 5. 
RNA isolation 
 RNA was isolated using the standard Trizol protocol provided by Invitrogen (Invitrogen, 
Carlsbad, CA) 
Microarray 
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 Microarray was performed as previously described [81] using the Affymetrix Human 
Genome, HG-U133A 2.0 Array chipset.  Control RNA was isolated from non transfected 
HEK293t cells.  
 
Results 
Table A1.  Top upregulated genes identified in HEK293t cells overexpressing RAI1. 
RAI1/Control Signal 
Log Ratio Gene Symbol Gene Name Pathway Biological Process 
5.5 TRPC1 
transient receptor 
potential cation 
channel, subfamily 
C, member 1 --- transport 
5.5 HNRNPU 
heterogeneous 
nuclear 
ribonucleoprotein U mRNA_processing_Reactome RNA processing 
5.3 MAT2A 
methionine 
adenosyltransferase 
II, alpha --- 
S-
adenosylmethionine 
biosynthetic 
process 
5 SRP72 
signal recognition 
particle 72kDa --- 
protein amino acid 
phosphorylation /// 
SRP-dependent 
cotranslational 
protein targeting to 
membrane /// signal 
transduction 
5 SAR1A 
SAR1 gene homolog 
A --- transport 
5 EZR ezrin --- 
cytoskeletal 
anchoring /// 
regulation of cell 
shape 
5 PSAT1 
phosphoserine 
aminotransferase 1 --- 
L-serine 
biosynthetic 
process 
4.9 SELT selenoprotein T --- 
selenocysteine 
incorporation /// 
cell redox 
homeostasis 
4.8 ASL 
argininosuccinate 
lyase --- urea cycle 
4.8 TP53 tumor protein p53 Apoptosis 
response to tumor 
cell 
4.8 PRIM2 
primase, DNA, 
polypeptide 2 
(58kDa) DNA_replication_Reactome DNA replication 
4.7 UBE2M 
ubiquitin-
conjugating enzyme 
E2M --- 
protein 
modification 
process 
///regulation of 
protein metabolic 
process 
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4.7 TMED2 
transmembrane 
emp24 domain 
trafficking protein 2 --- transport 
4.7 ENO1 enolase 1, (alpha) Glycolysis_and_Gluconeogenesis 
negative regulation 
of transcription 
from RNA 
polymerase II 
promoter /// 
glycolysis 
4.6 MRPS12 
mitochondrial 
ribosomal protein 
S12 --- translation 
4.6 RNFT1 
ring finger protein, 
transmembrane 1 --- --- 
4.5 DUSP3 
dual specificity 
phosphatase 3 --- 
protein amino acid 
dephosphorylation 
4.5 MAN1A1 
mannosidase, alpha, 
class 1A, member 1 --- 
protein amino acid 
glycosylation 
4.5 HIPK3 
homeodomain 
interacting protein 
kinase 3 --- transcription 
4.5 ADAM10 
ADAM 
metallopeptidase 
domain 10 Hypertrophy_model 
in utero embryonic 
development 
4.5 ARFRP1 
ADP-ribosylation 
factor related protein 
1 --- 
signal transduction 
/// small GTPase 
mediated signal 
transduction 
4.4 SLC29A1 
solute carrier family 
29 member 1 --- 
nucleobase, 
nucleoside, 
nucleotide and 
nucleic acid 
metabolic process 
4.4 HSPA8 
heat shock 70kDa 
protein 8 Circadian_Exercise 
protein folding /// 
response to stress 
/// response to 
unfolded protein 
4.3 UTRN utrophin --- 
muscle contraction 
/// muscle 
development 
4.3 PGK1 
phosphoglycerate 
kinase 1 Glycolysis_and_Gluconeogenesis 
glycolysis /// 
phosphorylation 
4.3 GDAP1 
ganglioside-induced 
differentiation-
associated protein 1 --- --- 
 
 
Table A2.  Top downregulated genes identified in HEK293t cells overexpressing RAI1 
RAI1/Control Signal 
Log Ratio Gene Symbol Gene Title Pathway Biological process term 
-5.5 ANKRD36B 
ankyrin repeat 
domain 36B --- 
cellular di-, tri-valent 
inorganic anion 
homeostasis 
-4.5 CDC42BPA 
CDC42 binding 
protein kinase alpha --- 
protein amino acid 
phosphorylation 
-4.2 SPEN 
spen homolog, 
transcriptional 
regulator --- transcription 
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-4.2 SFRS11 
splicing factor, 
arginine/serine-rich 
11 --- mRNA processing 
-4.2 SEMA6A 
sema domain, 
transmembrane 
domain, and 
cytoplasmic domain, 
6A --- 
apoptosis ///nervous system 
development /// axon 
guidance /// organ 
morphogenesis 
-4.1 NKTR 
natural killer-tumor 
recognition 
sequence --- protein folding 
-4.1 SMA4 
Glucuronidase, beta 
pseudogene 1 --- 
skeletal development /// 
carbohydrate metabolic 
process /// nervous system 
development 
-4 SRRM2 
serine/arginine 
repetitive matrix 2 --- mRNA processing 
-3.9 RBM41 
RNA binding motif 
protein 41 --- --- 
-3.7 MSH5 
mutS homolog 5 (E. 
coli) /// chromosome 
6 open reading 
frame 26 Ovarian_Infertility_Genes mismatch repair 
-3.7 GOLGA8A 
golgi autoantigen, 
golgin subfamily a, 
8A --- --- 
-3.7 CEP350 
centrosomal protein 
350kDa --- protein targeting 
-3.7 ATHL1 
ATH1, acid 
trehalase-like 1 --- 
carbohydrate metabolic 
process 
-3.7 EBF2 early B-cell factor 2 --- transcription 
-3.7 MCM3APAS 
minichromosome 
maintenance 
complex component 
3 associated protein 
antisense --- --- 
-3.7 WNK1 
WNK lysine 
deficient protein 
kinase 1 --- 
protein amino acid 
phosphorylation 
-3.6 ATRX 
alpha 
thalassemia/mental 
retardation 
syndrome X-linked --- 
DNA repair /// DNA repair 
/// DNA methylation 
 
 
Discussion 
 
 In this study we have overexpressed RAI1 in HEK293t cells to evaluate the molecular 
consequences of this action.  Given that RAI1 is a dosage sensitive gene these were important 
experiments to perform and examine pathways affected.  We have identified gene which play 
critical roles in circadian rhythm, epigenetic regulation, DNA repair, RNA processing, 
transcription and a variety of other critical pathways.  These studies will help to identify the 
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molecular role RAI1 plays in the cell and help to understand the consequence of abnormal RAI1 
dosage.  
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Overlapping genes identified in ChIP-Chip study (full names) 
ATP-binding cassette, sub-family B (MDR/TAP), member 1;ABCB1 
ATP-binding cassette, sub-family B (MDR/TAP), member 1;ABCB1 
amylo-1, 6-glucosidase, 4-alpha-glucanotransferase (glycogen debranching enzyme, 
glycogen storage disease type III);AGL 
amylo-1, 6-glucosidase, 4-alpha-glucanotransferase (glycogen debranching enzyme, 
glycogen storage disease type III);AGL 
A kinase (PRKA) anchor protein 7;AKAP7 
A kinase (PRKA) anchor protein 7;AKAP7 
aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-
alpha)-hydroxysteroid dehydrogenase);AKR1C1 
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type 
II);AKR1C3 
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type 
II);AKR1C3 
amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 16;ALS2CR16 
amelogenin, Y-linked;AMELY 
amelogenin, Y-linked;AMELY 
amylase, alpha 2A; pancreatic;AMY2A 
amylase, alpha 2B (pancreatic);AMY2B 
annexin A1;ANXA1 
annexin A1;ANXA1 
APin protein;APIN 
adenine phosphoribosyltransferase;APRT 
adenine phosphoribosyltransferase;APRT 
Rho guanine nucleotide exchange factor (GEF) 7;ARHGEF7 
Rho guanine nucleotide exchange factor (GEF) 7;ARHGEF7 
N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2;ASAH2 
N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2;ASAH2 
ankyrin repeat and SOCS box-containing 4;ASB4 
activating transcription factor 6;ATF6 
activating transcription factor 6;ATF6 
ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit;ATP5E 
ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit;ATP5E 
5-azacytidine induced 2;AZI2 
5-azacytidine induced 2;AZI2 
bromodomain adjacent to zinc finger domain, 2B;BAZ2B 
bromodomain adjacent to zinc finger domain, 2B;BAZ2B 
butyrylcholinesterase;BCHE 
butyrylcholinesterase;BCHE 
bone morphogenetic protein 5;BMP5 
bone morphogenetic protein 5;BMP5 
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chromosome 10 open reading frame 61;C10orf61 
chromosome 10 open reading frame 61;C10orf61 
chromosome 10 open reading frame 68;C10orf68 
chromosome 10 open reading frame 68;C10orf68 
chromosome 14 open reading frame 10;C14orf10 
chromosome 14 open reading frame 10;C14orf10 
chromosome 14 open reading frame 150;C14orf150 
chromosome 16 open reading frame 73;C16orf73 
chromosome 18 open reading frame 9;C18orf9 
chromosome 20 open reading frame 103;C20orf103 
chromosome 20 open reading frame 103;C20orf103 
chromosome 21 open reading frame 34;C21orf34 
chromosome 21 open reading frame 34;C21orf34 
chromosome 3 open reading frame 58;C3orf58 
complement component 4 binding protein, beta;C4BPB 
complement component 4 binding protein, beta;C4BPB 
chromosome 4 open reading frame 22;C4orf22 
chromosome 4 open reading frame 7;C4orf7 
chromosome 4 open reading frame 7;C4orf7 
chromosome 5 open reading frame 36;C5orf36 
chromosome 9 open reading frame 102;C9orf102 
chromosome 9 open reading frame 150;C9orf150 
chromosome 9 open reading frame 150;C9orf150 
calcium binding protein 39-like;CAB39L 
calcium binding protein 39-like;CAB39L 
coiled-coil domain containing 46;CCDC46 
CD69 antigen (p60, early T-cell activation antigen);CD69 
CD69 molecule;CD69 
cadherin 12, type 2 (N-cadherin 2);CDH12 
cadherin 12, type 2 (N-cadherin 2);CDH12 
chromodomain protein, Y-linked, 2B;CDY2B 
centaurin, delta 1;CENTD1 
centaurin, delta 1;CENTD1 
centrosomal protein 76kDa;CEP76 
choline/ethanolamine phosphotransferase 1;CEPT1 
choline/ethanolamine phosphotransferase 1;CEPT1 
complement factor H;CFH 
cell adhesion molecule with homology to L1CAM (close homolog of L1);CHL1 
cell adhesion molecule with homology to L1CAM (close homolog of L1);CHL1 
chondrolectin;CHODL 
chondrolectin;CHODL 
cholinergic receptor, nicotinic, alpha 5;CHRNA5 
cholinergic receptor, nicotinic, alpha polypeptide 5;CHRNA5 
C-type lectin domain family 5, member A;CLEC5A 
C-type lectin domain family 5, member A;CLEC5A 
ciliary neurotrophic factor;CNTF 
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ciliary neurotrophic factor;CNTF 
component of oligomeric golgi complex 6;COG6 
component of oligomeric golgi complex 6;COG6 
COMM domain containing 3;COMMD3 
cereblon;CRBN 
cereblon;CRBN 
cAMP responsive element modulator;CREM 
cAMP responsive element modulator;CREM 
crystallin, gamma S;CRYGS 
crystallin, gamma S;CRYGS 
cylicin, basic protein of sperm head cytoskeleton 2;CYLC2 
cylicin, basic protein of sperm head cytoskeleton 2;CYLC2 
chromosome Y open reading frame 15A;CYorf15A 
chromosome Y open reading frame 15B;CYorf15B 
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1-like helicase homolog, S. 
cerevisiae);DDX11 
defensin, beta 112;DEFB112 
defensin, beta 112;DEFB112 
diacylglycerol kinase, beta 90kDa;DGKB 
diacylglycerol kinase, beta 90kDa;DGKB 
diaphanous homolog 3 (Drosophila);DIAPH3 
diaphanous homolog 3 (Drosophila);DIAPH3 
DnaJ (Hsp40) homolog, subfamily C, member 5 beta;DNAJC5B 
DnaJ (Hsp40) homolog, subfamily C, member 5 beta;DNAJC5B 
dentin sialophosphoprotein;DSPP 
dentin sialophosphoprotein;DSPP 
dystrobrevin, alpha;DTNA 
dystrobrevin, alpha;DTNA 
elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 
2;ELOVL2 
elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 
2;ELOVL2 
eyes absent homolog 1 (Drosophila);EYA1 
eyes absent homolog 1 (Drosophila);EYA1 
family with sequence similarity 55, member D;FAM55D 
family with sequence similarity 55, member D;FAM55D 
F-box and leucine-rich repeat protein 7;FBXL7 
F-box and leucine-rich repeat protein 7;FBXL7 
F-box protein 4;FBXO4 
fibrinogen beta chain;FGB 
fibrinogen beta chain;FGB 
fibroblast growth factor 7 (keratinocyte growth factor);FGF7 
fibrinogen-like 2;FGL2 
fibrinogen-like 2;FGL2 
fumarate hydratase;FH 
fumarate hydratase;FH 
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hypothetical protein FLJ22662;FLJ22662 
hypothetical protein FLJ32745;FLJ32745 
FLJ44048 protein;FLJ44048 
forkhead box K2;FOXK2 
forkhead box K2;FOXK2 
forty-two-three domain containing 1;FYTTD1 
forty-two-three domain containing 1;FYTTD1 
gamma-aminobutyric acid (GABA) A receptor, gamma 1;GABRG1 
gamma-aminobutyric acid (GABA) A receptor, gamma 1;GABRG1 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 13 
(GalNAc-T13);GALNT13 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 13 
(GalNAc-T13);GALNT13 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-
like 2;GALNTL2 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-
like 2;GALNTL2 
GDNF family receptor alpha like;GFRAL 
glycine receptor, alpha 3;GLRA3 
glycine receptor, alpha 3;GLRA3 
G protein-coupled receptor 52;GPR52 
G protein-coupled receptor 52;GPR52 
HERV-H LTR-associating 2;HHLA2 
HERV-H LTR-associating 2;HHLA2 
histone 1, H2ac;HIST1H2AC 
histone cluster 1, H2ac;HIST1H2AC 
histone 1, H2bl;HIST1H2BL 
histone cluster 1, H2bl;HIST1H2BL 
histone 1, H2bm;HIST1H2BM 
histone cluster 1, H2bm;HIST1H2BM 
histone cluster 1, H3h;HIST1H3H 
histone 1, H4b;HIST1H4B 
histone cluster 1, H4b;HIST1H4B 
histone cluster 1, H4j;HIST1H4J 
major histocompatibility complex, class II, DP alpha 1;HLA-DPA1 
major histocompatibility complex, class II, DP alpha 1;HLA-DPA1 
major histocompatibility complex, class II, DP beta 1;HLA-DPB1 
major histocompatibility complex, class II, DP beta 1;HLA-DPB1 
hypothetical protein HS322B1A;HS322B1A 
heat shock transcription factor, Y-linked 1;HSFY1 
heat shock transcription factor, Y linked 2;HSFY2 
hereditary sensory neuropathy, type II;HSN2 
5-hydroxytryptamine (serotonin) receptor 2B;HTR2B 
5-hydroxytryptamine (serotonin) receptor 2B;HTR2B 
interferon, alpha 10;IFNA10 
interleukin 12 receptor, beta 2;IL12RB2 
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interleukin 12 receptor, beta 2;IL12RB2 
interleukin 15;IL15 
interleukin 15;IL15 
interleukin 17D;IL17D 
interleukin 17D;IL17D 
interphotoreceptor matrix proteoglycan 2;IMPG2 
interphotoreceptor matrix proteoglycan 2;IMPG2 
inversin;INVS 
inversin;INVS 
jumonji domain containing 1A;JMJD1A 
jumonji domain containing 1A;JMJD1A 
potassium channel, subfamily K, member 10;KCNK10 
potassium channel, subfamily K, member 10;KCNK10 
potassium large conductance calcium-activated channel, subfamily M, beta member 
4;KCNMB4 
potassium large conductance calcium-activated channel, subfamily M, beta member 
4;KCNMB4 
potassium channel tetramerisation domain containing 4;KCTD4 
potassium channel tetramerisation domain containing 4;KCTD4 
KIAA0391;KIAA0391 
KIAA0391;KIAA0391 
KIAA1712;KIAA1712 
KIAA1712;KIAA1712 
Kruppel-like factor 14;KLF14 
Kruppel-like factor 14;KLF14 
kelch-like 4 (Drosophila);KLHL4 
kelch-like 4 (Drosophila);KLHL4 
kelch-like 9 (Drosophila);KLHL9 
kelch-like 9 (Drosophila);KLHL9 
killer cell lectin-like receptor subfamily C, member 4;KLRC4 
killer cell lectin-like receptor subfamily K, member 1;KLRK1 
keratin 12 (Meesmann corneal dystrophy);KRT12 
keratin 12 (Meesmann corneal dystrophy);KRT12 
keratin 24;KRT24 
keratin 24;KRT24 
keratin associated protein 1-1;KRTAP1-1 
keratin associated protein 1-1;KRTAP1-1 
keratin associated protein 1-3;KRTAP1-3 
keratin associated protein 1-3;KRTAP1-3 
keratin associated protein 4-12;KRTAP4-12 
keratin associated protein 4-12;KRTAP4-12 
keratin associated protein 6-3;KRTAP6-3 
late cornified envelope 3B;LCE3B 
late cornified envelope 3B;LCE3B 
low density lipoprotein receptor (familial hypercholesterolemia);LDLR 
low density lipoprotein receptor (familial hypercholesterolemia);LDLR 
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lymphoid enhancer-binding factor 1;LEF1 
smooth muscle myosin heavy chain 11 isoform SM1-like;LOC129285 
C/EBP-induced protein;LOC81558 
latrophilin 2;LPHN2 
latrophilin 2;LPHN2 
leucine rich repeat neuronal 3;LRRN3 
leucine rich repeat neuronal 3;LRRN3 
leucine rich repeat transmembrane neuronal 4;LRRTM4 
leucine rich repeat transmembrane neuronal 4;LRRTM4 
liver-specific organic anion transporter 3;LST-3 
lumican;LUM 
lumican;LUM 
MAS1 oncogene-like;MAS1L 
MAS1 oncogene-like;MAS1L 
MADS box transcription enhancer factor 2, polypeptide A (myocyte enhancer factor 
2A);MEF2A 
MADS box transcription enhancer factor 2, polypeptide A (myocyte enhancer factor 
2A);MEF2A 
meprin A, alpha (PABA peptide hydrolase);MEP1A 
meprin A, alpha (PABA peptide hydrolase);MEP1A 
mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme 
C (putative);MGAT4C 
hypothetical protein MGC33530;MGC33530 
hypothetical protein MGC34713;MGC34713 
hypothetical protein MGC35043;MGC35043 
hypothetical protein MGC35212;MGC35212 
makorin, ring finger protein, 3;MKRN3 
makorin, ring finger protein, 3;MKRN3 
matrix metallopeptidase 13 (collagenase 3);MMP13 
matrix metallopeptidase 13 (collagenase 3);MMP13 
mitochondrial translational release factor 1-like;MTRF1L 
mitochondrial translational release factor 1-like;MTRF1L 
mucin 7, salivary;MUC7 
mucin 7, secreted;MUC7 
myosin, light chain 1, alkali; skeletal, fast;MYL1 
myosin, light polypeptide 1, alkali; skeletal, fast;MYL1 
nucleosome assembly protein 1-like 3;NAP1L3 
nucleosome assembly protein 1-like 3;NAP1L3 
odontogenic, ameloblast asssociated;ODAM 
osteoglycin (osteoinductive factor, mimecan);OGN 
osteoglycin (osteoinductive factor, mimecan);OGN 
osteomodulin;OMD 
osteomodulin;OMD 
olfactory receptor, family 10, subfamily T, member 2;OR10T2 
olfactory receptor, family 10, subfamily T, member 2;OR10T2 
olfactory receptor, family 11, subfamily H, member 4;OR11H4 
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olfactory receptor, family 11, subfamily H, member 4;OR11H4 
olfactory receptor, family 13, subfamily C, member 3;OR13C3 
olfactory receptor, family 13, subfamily C, member 3;OR13C3 
olfactory receptor, family 13, subfamily F, member 1;OR13F1 
olfactory receptor, family 13, subfamily F, member 1;OR13F1 
olfactory receptor, family 1, subfamily Q, member 1;OR1Q1 
olfactory receptor, family 1, subfamily Q, member 1;OR1Q1 
olfactory receptor, family 2, subfamily B, member 11;OR2B11 
olfactory receptor, family 2, subfamily J, member 3;OR2J3 
olfactory receptor, family 2, subfamily L, member 2;OR2L2 
olfactory receptor, family 2, subfamily L, member 2;OR2L2 
olfactory receptor, family 2, subfamily L, member 3;OR2L3 
olfactory receptor, family 2, subfamily M, member 5;OR2M5 
olfactory receptor, family 2, subfamily T, member 10;OR2T10 
olfactory receptor, family 2, subfamily T, member 4;OR2T4 
olfactory receptor, family 4, subfamily A, member 47;OR4A47 
olfactory receptor, family 4, subfamily C, member 16;OR4C16 
olfactory receptor, family 4, subfamily C, member 16;OR4C16 
olfactory receptor, family 51, subfamily A, member 7;OR51A7 
olfactory receptor, family 51, subfamily A, member 7;OR51A7 
olfactory receptor, family 52, subfamily A, member 1;OR52A1 
olfactory receptor, family 52, subfamily A, member 1;OR52A1 
olfactory receptor, family 52, subfamily N, member 5;OR52N5 
olfactory receptor, family 52, subfamily N, member 5;OR52N5 
olfactory receptor, family 56, subfamily B, member 1;OR56B1 
olfactory receptor, family 56, subfamily B, member 1;OR56B1 
olfactory receptor, family 5, subfamily B, member 2;OR5B2 
olfactory receptor, family 5, subfamily BU, member 1;OR5BU1 
olfactory receptor, family 5, subfamily H, member 14;OR5H14 
olfactory receptor, family 5, subfamily H, member 6;OR5H6 
olfactory receptor, family 5, subfamily H, member 6;OR5H6 
olfactory receptor, family 5, subfamily K, member 3;OR5K3 
olfactory receptor, family 5, subfamily K, member 4;OR5K4 
olfactory receptor, family 5, subfamily M, member 3;OR5M3 
olfactory receptor, family 5, subfamily M, member 3;OR5M3 
olfactory receptor, family 5, subfamily R, member 1;OR5R1 
olfactory receptor, family 5, subfamily T, member 2;OR5T2 
olfactory receptor, family 5, subfamily T, member 2;OR5T2 
olfactory receptor, family 5, subfamily V, member 1;OR5V1 
olfactory receptor, family 5, subfamily V, member 1;OR5V1 
olfactory receptor, family 5, subfamily W, member 2;OR5W2 
olfactory receptor, family 6, subfamily M, member 1;OR6M1 
olfactory receptor, family 6, subfamily M, member 1;OR6M1 
olfactory receptor, family 8, subfamily H, member 1;OR8H1 
olfactory receptor, family 8, subfamily H, member 2;OR8H2 
olfactory receptor, family 8, subfamily H, member 2;OR8H2 
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olfactory receptor, family 8, subfamily I, member 2;OR8I2 
olfactory receptor, family 8, subfamily I, member 2;OR8I2 
olfactory receptor, family 8, subfamily K, member 3;OR8K3 
olfactory receptor, family 8, subfamily K, member 3;OR8K3 
olfactory receptor, family 9, subfamily G, member 1;OR9G1 
olfactory receptor, family 9, subfamily G, member 1;OR9G1 
olfactory receptor, family 9, subfamily G, member 9;OR9G9 
OTU domain containing 6B;OTUD6B 
OTU domain containing 6B;OTUD6B 
palladin, cytoskeletal associated protein;PALLD 
protocadherin 11 X-linked;PCDH11X 
protocadherin 11 Y-linked;PCDH11Y 
protocadherin 15;PCDH15 
protocadherin 15;PCDH15 
protocadherin alpha 1;PCDHA1 
protocadherin alpha 11;PCDHA11 
protocadherin alpha 3;PCDHA3 
protocadherin beta 16;PCDHB16 
protocadherin beta 16;PCDHB16 
protocadherin beta 8;PCDHB8 
protocadherin beta 8;PCDHB8 
protocadherin gamma subfamily A, 12;PCDHGA12 
protocadherin gamma subfamily A, 9;PCDHGA9 
phosphodiesterase 1A, calmodulin-dependent;PDE1A 
phosphodiesterase 1A, calmodulin-dependent;PDE1A 
pleckstrin homology domain interacting protein;PHIP 
phytanoyl-CoA 2-hydroxylase interacting protein-like;PHYHIPL 
phytanoyl-CoA hydroxylase interacting protein-like;PHYHIPL 
phosphatidylinositol glycan anchor biosynthesis, class F;PIGF 
phosphatidylinositol glycan, class F;PIGF 
phospholipase C, beta 4;PLCB4 
phospholipase C, beta 4;PLCB4 
pleiotropic regulator 1 (PRL1 homolog, Arabidopsis);PLRG1 
pleiotropic regulator 1 (PRL1 homolog, Arabidopsis);PLRG1 
pro-melanin-concentrating hormone;PMCH 
pancreatic lipase;PNLIP 
pancreatic lipase;PNLIP 
POU domain, class 1, transcription factor 1 (Pit1, growth hormone factor 1);POU1F1 
POU domain, class 1, transcription factor 1 (Pit1, growth hormone factor 1);POU1F1 
protein kinase, cAMP-dependent, catalytic, beta;PRKACB 
protein kinase, cAMP-dependent, catalytic, beta;PRKACB 
RAP1B, member of RAS oncogene family;RAP1B 
RAP1B, member of RAS oncogene family;RAP1B 
regulator of G-protein signalling 21;RGS21 
ras homolog gene family, member B;RHOB 
ras homolog gene family, member B;RHOB 
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ring finger protein 17;RNF17 
ras responsive element binding protein 1;RREB1 
ras responsive element binding protein 1;RREB1 
arginine/serine-rich coiled-coil 1;RSRC1 
arginine/serine-rich coiled-coil 1;RSRC1 
serpin peptidase inhibitor, clade I (pancpin), member 2;SERPINI2 
serpin peptidase inhibitor, clade I (pancpin), member 2;SERPINI2 
sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein);SGCG 
sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein);SGCG 
sarcoglycan zeta;SGCZ 
sarcoglycan zeta;SGCZ 
short stature homeobox 2;SHOX2 
short stature homeobox 2;SHOX2 
sucrase-isomaltase (alpha-glucosidase);SI 
sucrase-isomaltase (alpha-glucosidase);SI 
silver homolog (mouse);SILV 
silver homolog (mouse);SILV 
solute carrier family 12 (sodium/potassium/chloride transporters), member 1;SLC12A1 
solute carrier family 12 (sodium/potassium/chloride transporters), member 1;SLC12A1 
solute carrier family 16 (monocarboxylic acid transporters), member 7;SLC16A7 
solute carrier family 16, member 7 (monocarboxylic acid transporter 2);SLC16A7 
solute carrier family 25, member 32;SLC25A32 
solute carrier family 25, member 32;SLC25A32 
solute carrier family 26, member 7;SLC26A7 
solute carrier family 26, member 7;SLC26A7 
solute carrier organic anion transporter family, member 1B3;SLCO1B3 
solute carrier organic anion transporter family, member 1B3;SLCO1B3 
SLIT and NTRK-like family, member 6;SLITRK6 
SLIT and NTRK-like family, member 6;SLITRK6 
structural maintenance of chromosomes 6;SMC6 
SMC6 structural maintenance of chromosomes 6-like 1 (yeast);SMC6L1 
syntaphilin;SNPH 
syntaphilin;SNPH 
small nuclear ribonucleoprotein polypeptide N;SNRPN 
Sp6 transcription factor;SP6 
Sp6 transcription factor;SP6 
sperm associated antigen 6;SPAG6 
sperm associated antigen 6;SPAG6 
sperm protein associated with the nucleus, X-linked, family member A1;SPANXA1 
SPANX family, member A2;SPANXA2 
SPANX family, member E;SPANXE 
spermatogenesis associated 18 homolog (rat);SPATA18 
spermatogenesis associated 18 homolog (rat);SPATA18 
TAF2 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
150kDa;TAF2 
TAF2 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
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150kDa;TAF2 
TGF-beta induced apotosis protein 2;TAIP-2 
taste receptor, type 2, member 7;TAS2R7 
taste receptor, type 2, member 7;TAS2R7 
taste receptor, type 2, member 8;TAS2R8 
taste receptor, type 2, member 8;TAS2R8 
tudor domain containing 4;TDRD4 
testis expressed sequence 15;TEX15 
testis expressed sequence 15;TEX15 
transcription factor EC;TFEC 
transcription factor EC;TFEC 
transmembrane protein 77;TMEM77 
transmembrane protein 77;TMEM77 
transmembrane protease, serine 11B;TMPRSS11B 
transmembrane protease, serine 11B;TMPRSS11B 
tumor necrosis factor (ligand) superfamily, member 18;TNFSF18 
tumor necrosis factor (ligand) superfamily, member 18;TNFSF18 
tumor necrosis factor superfamily, member 5-induced protein 1;TNFSF5IP1 
tumor necrosis factor superfamily, member 5-induced protein 1;TNFSF5IP1 
transient receptor potential cation channel, subfamily C, member 3;TRPC3 
transient receptor potential cation channel, subfamily C, member 3;TRPC3 
transient receptor potential cation channel, subfamily M, member 8;TRPM8 
transient receptor potential cation channel, subfamily M, member 8;TRPM8 
tumor suppressor candidate 1;TUSC1 
tumor suppressor candidate 1;TUSC1 
thioredoxin domain containing 13;TXNDC13 
ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, Angelman 
syndrome);UBE3A 
ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, Angelman 
syndrome);UBE3A 
ubiquitin-fold modifier 1;UFM1 
ubiquitin-fold modifier 1;UFM1 
UDP glucuronosyltransferase 2 family, polypeptide A1;UGT2A1 
UDP glucuronosyltransferase 2 family, polypeptide A1;UGT2A1 
IVFI9356;UNQ9356 
urotensin 2 domain containing;UTS2D 
urotensin 2 domain containing;UTS2D 
ubiquitously transcribed tetratricopeptide repeat gene, Y-linked;UTY 
ubiquitously transcribed tetratricopeptide repeat gene, Y-linked;UTY 
V-set and transmembrane domain containing 2;VSTM2 
von Willebrand factor A domain containing 2;VWA2 
WD repeat domain 89;WDR89 
WD repeats and SOF1 domain containing;WDSOF1 
WD repeats and SOF1 domain containing;WDSOF1 
5'-3&apos; exoribonuclease 1;XRN1 
5'-3' exoribonuclease 1;XRN1 
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Yip1 domain family, member 7;YIPF7 
Yip1 domain family, member 7;YIPF7 
zinc finger protein 306;ZNF306 
zinc finger protein 306;ZNF306 
zinc finger protein 614;ZNF614 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
